Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6524719,elimination half-life,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),h,11.9,3370,DB01223,Aminophylline
,6524719,distribution half-life,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),h,0.495,3371,DB01223,Aminophylline
,6524719,apparent specific volume of distribution,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[l] / [kg],0.885,3372,DB01223,Aminophylline
,6524719,apparent specific volume of central compartment,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[l] / [kg],0.080,3373,DB01223,Aminophylline
,6524719,clearance,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[ml] / [h·kg],51.7,3374,DB01223,Aminophylline
,6524719,PaCO2,"The horses at 0.5 hour after dosing had a significant decrease in PaCO2 (43.6 +/- 5.5 to 39.4 +/- 6.7 mm of Hg, P less than 0.001) and a significant increase in blood pH (7.38 +/- 0.017 to 7.41 +/- 0.023, P less than 0.001).",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),hg·mm,43.6,3375,DB01223,Aminophylline
,6524719,PaCO2,"The horses at 0.5 hour after dosing had a significant decrease in PaCO2 (43.6 +/- 5.5 to 39.4 +/- 6.7 mm of Hg, P less than 0.001) and a significant increase in blood pH (7.38 +/- 0.017 to 7.41 +/- 0.023, P less than 0.001).",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),hg·mm,39.4,3376,DB01223,Aminophylline
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,5.9,4081,DB01223,Aminophylline
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,7.3,4082,DB01223,Aminophylline
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.065,4083,DB01223,Aminophylline
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.049,4084,DB01223,Aminophylline
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,42.8,5359,DB01223,Aminophylline
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,81.9,5360,DB01223,Aminophylline
,1926271,CL/F,Both these parameters were found to significantly correlate to weight alone in a directly proportional manner: CL/F = 40 +/- 2 ml/h/kg and V/F = 1.3 +/- 0.2 L/kg.,Population pharmacokinetics of rectal theophylline in neonates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),[ml] / [h·kg],40,5901,DB01223,Aminophylline
,1926271,V/F,Both these parameters were found to significantly correlate to weight alone in a directly proportional manner: CL/F = 40 +/- 2 ml/h/kg and V/F = 1.3 +/- 0.2 L/kg.,Population pharmacokinetics of rectal theophylline in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),[l] / [kg],1.3,5902,DB01223,Aminophylline
,1926271,half-life,"The absorption was best described by a first-order process, having a half-life of 1.6 +/- 0.7 h.",Population pharmacokinetics of rectal theophylline in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),h,1.6,5903,DB01223,Aminophylline
,3273483,minimum,"When Uniphyl was administered with food, bioavailability was increased by 10% (p less than 0.01), the time of maximum concentration occurred 3 hours later (p less than 0.01), and the minimum or ""trough"" theophylline concentration was 0.7 mg/L greater (p less than 0.01), as compared to administration while patients were fasting.",The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3273483/),[mg] / [l],0.7,7014,DB01223,Aminophylline
,7431219,bioavailability,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,100.2,7068,DB01223,Aminophylline
,7431219,bioavailability,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,98.5,7069,DB01223,Aminophylline
,7431219,peak times,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,10.4,7070,DB01223,Aminophylline
,7431219,peak times,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,4.36,7071,DB01223,Aminophylline
,7431219,peak plasma concentrations,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],13.9,7072,DB01223,Aminophylline
,7431219,peak plasma concentrations,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],22.6,7073,DB01223,Aminophylline
,7431219,tpeak,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,1.52,7074,DB01223,Aminophylline
,7431219,Cpeak,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],28.1,7075,DB01223,Aminophylline
,7431219,time of the plasma concentration peak,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,2.47,7076,DB01223,Aminophylline
,7431219,peak concentration,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],16.0,7077,DB01223,Aminophylline
,7431219,availability,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,76.0,7078,DB01223,Aminophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),ng,0-15,7099,DB01223,Aminophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),nM,0-46,7100,DB01223,Aminophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μg,10-85,7101,DB01223,Aminophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μM,50-429,7102,DB01223,Aminophylline
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,5.7,8319,DB01223,Aminophylline
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,9.2,8320,DB01223,Aminophylline
,32919393,half-life,The median half-life was 39.5 h (range 27.2-50.4).,Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32919393/),h,39.5,9086,DB01223,Aminophylline
,3407413,t1/2 alpha,After the intravenous administration the distribution is relatively fast (t1/2 alpha = 3.28h).,Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),h,3.28,11791,DB01223,Aminophylline
,3407413,apparent volume of distribution,High values of the apparent volume of distribution--12.15 1/kg suggest tissue accumulation.,Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),[1] / [kg],12.15,11792,DB01223,Aminophylline
,3407413,t1/2 beta,"Elimination is considerably slower (t1/2 beta = 19,00 h) than distribution.",Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),h,"19,00",11793,DB01223,Aminophylline
,688731,total clearance,Theophylline was cleared from the blood more rapidly in both marihuana and tobacco smokers with a mean increase in total clearance from 52 ml/kg/hr in nonsmokers to 74 ml/kg/hr in subjects who smoked either material alone.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],52,13215,DB01223,Aminophylline
,688731,total clearance,Theophylline was cleared from the blood more rapidly in both marihuana and tobacco smokers with a mean increase in total clearance from 52 ml/kg/hr in nonsmokers to 74 ml/kg/hr in subjects who smoked either material alone.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],74,13216,DB01223,Aminophylline
,688731,clearance,There was an additive increase in clearance to 93 ml/kg/hr in those who smoked both substances.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],93,13217,DB01223,Aminophylline
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.77,15035,DB01223,Aminophylline
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.26,15036,DB01223,Aminophylline
,1664467,renal clearance (CLR),"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.75,15037,DB01223,Aminophylline
,1664467,CLR,"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.13,15038,DB01223,Aminophylline
,7229951,half-life,"After rapid intravenous doses of aminophylline, the theophylline half-life was 5-7 hr, which decreased slightly when the drug was administered concomitantly with caffeine during steady state of caffeine.",Effect of caffeine on circulating theophylline levels in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),h,5-7,20051,DB01223,Aminophylline
,7229951,volume of distribution,The theophylline volume of distribution (0.75 liter/kg) was unaffected by caffeine.,Effect of caffeine on circulating theophylline levels in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),[l] / [kg],0.75,20052,DB01223,Aminophylline
,884920,serum half-life (t1/2),"The serum concentration-time data were fitted to a two-compartment open model and yielded a mean serum half-life (t1/2) of 11.02 hr, a value longer than those previously reported.",Kinetics of intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884920/),h,11.02,21097,DB01223,Aminophylline
,2589989,Distribution volume (Vd),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),[ml] / [kg],385,22487,DB01223,Aminophylline
,2589989,Elimination rate constant (Ke),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),1/[h],0.155,22488,DB01223,Aminophylline
,2589989,Clearance (CL),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),[ml] / [h·kg],61.8,22489,DB01223,Aminophylline
,11483122,Maximum serum concentrations,Maximum serum concentrations ranged from 55 to 123 mg/L.,Theophylline toxicokinetics in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[mg] / [l],55 to 123,26529,DB01223,Aminophylline
,11483122,half-lives,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),h,24.7 to 36.5,26530,DB01223,Aminophylline
,11483122,clearance,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[l] / [h·kg],0.02 to 0.05,26531,DB01223,Aminophylline
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],249,29195,DB01223,Aminophylline
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],211,29196,DB01223,Aminophylline
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,51.1,29197,DB01223,Aminophylline
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,32.1,29198,DB01223,Aminophylline
,3709624,trough concentration,"With chronic oral dosing, however, the mean trough concentration was 12% higher at 9 a.m. than at 5 p.m., the end of the dose interval (3.94 +/- 0.55 vs. 3.50 +/- 0.45 micrograms X ml-1).",Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709624/),[μg] / [ml],3.94,30704,DB01223,Aminophylline
,3709624,trough concentration,"With chronic oral dosing, however, the mean trough concentration was 12% higher at 9 a.m. than at 5 p.m., the end of the dose interval (3.94 +/- 0.55 vs. 3.50 +/- 0.45 micrograms X ml-1).",Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709624/),[μg] / [ml],3.50,30705,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],56.2,33222,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],50.1,33223,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],58.7,33224,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],48.3,33225,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],65.7,33226,DB01223,Aminophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],52.1,33227,DB01223,Aminophylline
,6691624,T concentration,"The mean actual T concentration was 12.7 +/- 6.62 micrograms/mL, while the mean predicted T concentration was 11.4 +/- 5.37 micrograms/mL.",Prediction of serum theophylline levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691624/),[μg] / [ml],12.7,34847,DB01223,Aminophylline
,6691624,T concentration,"The mean actual T concentration was 12.7 +/- 6.62 micrograms/mL, while the mean predicted T concentration was 11.4 +/- 5.37 micrograms/mL.",Prediction of serum theophylline levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691624/),[μg] / [ml],11.4,34848,DB01223,Aminophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,7.2 to 15.4,37675,DB01223,Aminophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,9.4,37676,DB01223,Aminophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,5.4 to 27.2,37677,DB01223,Aminophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,14.4,37678,DB01223,Aminophylline
,6540112,Peak concentrations,Peak concentrations of theophylline in the plasma (7.5 +/- 1.6 micrograms/ml) are below those which are thought to produce concentration-dependent side effects.,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),[μg] / [ml],7.5,37679,DB01223,Aminophylline
,15083216,volume of distribution (Vd),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [kg],0.77,43855,DB01223,Aminophylline
,15083216,elimination rate constant (Ke),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),1/[h],0.027,43856,DB01223,Aminophylline
,15083216,CL,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [h·kg],0.019,43857,DB01223,Aminophylline
,15083216,t0.5,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),,30.7,43858,DB01223,Aminophylline
,15083216,Css level,"In view of the results and practical considerations, initial dosage regimen to attain a TH Css level within the therapeutic range (6-12 ug/ml) was suggested: LD 6-7 mg/kg, MD 1.5 - 2.0 mg/kg/12 hours.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[ug] / [ml],6-12,43859,DB01223,Aminophylline
,2371242,Vss,"In addition, the Vss decreased from 0.71 L/kg to 0.57 L/kg in the 2 and 20 month old rats, respectively, on a normal protein diet.",The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[l] / [kg],0.71,45391,DB01223,Aminophylline
,2371242,Vss,"In addition, the Vss decreased from 0.71 L/kg to 0.57 L/kg in the 2 and 20 month old rats, respectively, on a normal protein diet.",The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[l] / [kg],0.57,45392,DB01223,Aminophylline
,2371242,total body clearance,Dietary protein deficiency led to a significant reduction of total body clearance from approximately 73 to 45 ml/hr/kg in the 2 and 14 month old rats.,The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[ml] / [h·kg],73,45393,DB01223,Aminophylline
,2371242,total body clearance,Dietary protein deficiency led to a significant reduction of total body clearance from approximately 73 to 45 ml/hr/kg in the 2 and 14 month old rats.,The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[ml] / [h·kg],45,45394,DB01223,Aminophylline
,7341279,elimination half-live,"In this study, the elimination half-live increased from 7.8 +/- 1.7 h on the control day to 9.5 +/- 1.4 h following treatment with antibiotic (p less than 0.02).",The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),h,7.8,48541,DB01223,Aminophylline
,7341279,elimination half-live,"In this study, the elimination half-live increased from 7.8 +/- 1.7 h on the control day to 9.5 +/- 1.4 h following treatment with antibiotic (p less than 0.02).",The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),h,9.5,48542,DB01223,Aminophylline
,7341279,apparent volume of distribution for theophylline (V/F),The estimated apparent volume of distribution for theophylline (V/F) was also observed to increase from 0.42 +/- 0.09 l/kg before treatment with erythromycin to 0.53 +/- 0.15 l/kg after antibiotic treatment (0.05 less than p less than 0.10).,The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),[l] / [kg],0.42,48543,DB01223,Aminophylline
,7341279,apparent volume of distribution for theophylline (V/F),The estimated apparent volume of distribution for theophylline (V/F) was also observed to increase from 0.42 +/- 0.09 l/kg before treatment with erythromycin to 0.53 +/- 0.15 l/kg after antibiotic treatment (0.05 less than p less than 0.10).,The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),[l] / [kg],0.53,48544,DB01223,Aminophylline
,7202475,peak time,The mean peak time after oral administration was 29 min.,Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),min,29,49570,DB01223,Aminophylline
,7202475,fraction absorbed,"The mean fraction absorbed was 1.09 calculated from serum concentrations, and 1.05 calculated from urinary excretion of the drug.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),,1.09,49571,DB01223,Aminophylline
,7202475,fraction absorbed,"The mean fraction absorbed was 1.09 calculated from serum concentrations, and 1.05 calculated from urinary excretion of the drug.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),,1.05,49572,DB01223,Aminophylline
,7202475,apparent volume of distribution,"The apparent volume of distribution was 0.61 1/kg (0.53--0.72 1/kg), 26% higher in males than in females.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),[1] / [kg],0.61,49573,DB01223,Aminophylline
,7202475,distribution half-life,"A two-compartment open model was found to describe the decline in the serum concentrations, giving a mean distribution half-life of 6 min.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),min,6,49574,DB01223,Aminophylline
,7202475,biological half-life,"The intersubject ranges of biological half-life were 8.1--12.1 h and 8.3--12.6 h calculated from serum and urine data, respectively.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),h,8.,49575,DB01223,Aminophylline
,7202475,biological half-life,"The intersubject ranges of biological half-life were 8.1--12.1 h and 8.3--12.6 h calculated from serum and urine data, respectively.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),h,8.3,49576,DB01223,Aminophylline
,2274687,steady state concentrations,The plasma theophylline concentration after 8-10 h was then used to calculate the optimum maintenance dose of sustained release aminophylline required to achieve steady state concentrations between 55 and 110 mumols l-1.,A single oral dose method for predicting steady state theophylline concentrations in clinical practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2274687/),[mumols] / [l],55 and 110,52540,DB01223,Aminophylline
,2712416,elimination half-life,The drug had a mean elimination half-life of 6.4 hours and a mean distribution half-life of 22 minutes.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),h,6.4,52798,DB01223,Aminophylline
,2712416,distribution half-life,The drug had a mean elimination half-life of 6.4 hours and a mean distribution half-life of 22 minutes.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),min,22,52799,DB01223,Aminophylline
,2712416,Total body clearance,Total body clearance averaged 91 ml/kg/h.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[ml] / [h·kg],91,52800,DB01223,Aminophylline
,2712416,volume of the central compartment,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.502,52801,DB01223,Aminophylline
,2712416,volume of distribution during the terminal phase,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.870,52802,DB01223,Aminophylline
,2712416,volume of distribution at steady state,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.815,52803,DB01223,Aminophylline
,2712416,absorption half-life,"The plasma concentrations after oral dosing peaked in approximately 5 to 6 hours, with a mean absorption half-life of 3.7 hours.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),h,3.7,52804,DB01223,Aminophylline
,3429692,clearance,"First, a 600-mg oral dose of aminophylline, a rapidly absorbed formulation, was studied to confirm that theophylline clearance was in the expected range (mean +/- SD, 0.710 +/- 0.096 mL/min/kg), t1/2 = 6.9 +/- 1.1 hr.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[ml] / [kg·min],0.710,55705,DB01223,Aminophylline
,3429692,t1/2,"First, a 600-mg oral dose of aminophylline, a rapidly absorbed formulation, was studied to confirm that theophylline clearance was in the expected range (mean +/- SD, 0.710 +/- 0.096 mL/min/kg), t1/2 = 6.9 +/- 1.1 hr.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),h,6.9,55706,DB01223,Aminophylline
,3429692,Cmax,"Theophylline Cmax levels averaged 16.5 micrograms/mL after 900 mg Theo-Dur, with 8% exceeding 20 micrograms/mL.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],16.5,55707,DB01223,Aminophylline
,3429692,Cmax,"Theophylline Cmax levels averaged 16.5 micrograms/mL after 900 mg Theo-Dur, with 8% exceeding 20 micrograms/mL.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),,20,55708,DB01223,Aminophylline
,3429692,trough levels,Uniphyl administration resulted in three-fourths of trough levels to be at 5 micrograms/mL or lower.,"Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],5,55709,DB01223,Aminophylline
below,3429692,trough levels,"With Theo-24 only 17% of trough levels were below 5 micrograms/mL, as compared to 47% with Theo-Dur and 72% with Uniphyl.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],5,55710,DB01223,Aminophylline
,7349323,half-life (t1/2),Mean half-life (t1/2) of theophylline following single intravenous administration was 5.7 h and the apparent specific volume of distribution (V'd area) was 0.82 litre/kg.,Pharmacokinetic studies of theophylline in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),h,5.7,58052,DB01223,Aminophylline
,7349323,apparent specific volume of distribution (V'd area),Mean half-life (t1/2) of theophylline following single intravenous administration was 5.7 h and the apparent specific volume of distribution (V'd area) was 0.82 litre/kg.,Pharmacokinetic studies of theophylline in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),[l] / [kg],0.82,58053,DB01223,Aminophylline
,7349323,bioavailability,The bioavailability of theophylline was high (91%) following oral administration of aminophylline tablets and the absorption half-life (t1/2ab) was 0.4 h.,Pharmacokinetic studies of theophylline in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),%,91,58054,DB01223,Aminophylline
,7349323,absorption half-life (t1/2ab),The bioavailability of theophylline was high (91%) following oral administration of aminophylline tablets and the absorption half-life (t1/2ab) was 0.4 h.,Pharmacokinetic studies of theophylline in dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),h,0.4,58055,DB01223,Aminophylline
,7251238,Bioavailability,Bioavailability amounted to 111 +/- 16% (X +/- SD) compared to i. v. administration.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),%,111,59932,DB01223,Aminophylline
,7251238,time of peak theophylline concentration,Absorption from the sustained-release tablet appeared more erratic and less complete: the time of peak theophylline concentration varied between 2 and 14 h.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),h,2 and 14,59933,DB01223,Aminophylline
,7251238,bioavailability,The mean plasma level curve showed a plateau between 2 and 14 h bioavailability was 72 +/- 13%.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),%,72,59934,DB01223,Aminophylline
,7251238,peak theophylline concentrations,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],8.1,59935,DB01223,Aminophylline
,7251238,trough levels,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],6.2,59936,DB01223,Aminophylline
,7251238,trough levels,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],5.6,59937,DB01223,Aminophylline
,7286054,clearance,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),[ml] / [h·kg],78.6,62982,DB01223,Aminophylline
,7286054,half-life,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),h,4.14,62983,DB01223,Aminophylline
,7286054,apparent volume of distribution,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),[l] / [kg],0.41,62984,DB01223,Aminophylline
,3410380,half-time (T1/2 beta),"The half-time (T1/2 beta) of theophylline was 5.63 +/- 0.83 hr, and the volume of distribution (Vd) was 0.73 +/- 0.04 l/kg.","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),h,5.63,63550,DB01223,Aminophylline
,3410380,volume of distribution (Vd),"The half-time (T1/2 beta) of theophylline was 5.63 +/- 0.83 hr, and the volume of distribution (Vd) was 0.73 +/- 0.04 l/kg.","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),[l] / [kg],0.73,63551,DB01223,Aminophylline
,3410380,elimination rate constant,The elimination rate constant was 0.37 +/- 0.05 hr-1.,"[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),1/[h],0.37,63552,DB01223,Aminophylline
,3410380,bioavailability,"Absorption of theophylline (8.2 mg/kg, n = 5) administered intramuscularly was good as indicated by its high bioavailability (101.9 +/- 6.5%), but the value of bioavailability was low in oral administration (72.8 +/- 11.8%, n = 5).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,101.9,63553,DB01223,Aminophylline
,3410380,bioavailability,"Absorption of theophylline (8.2 mg/kg, n = 5) administered intramuscularly was good as indicated by its high bioavailability (101.9 +/- 6.5%), but the value of bioavailability was low in oral administration (72.8 +/- 11.8%, n = 5).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,72.8,63554,DB01223,Aminophylline
,3410380,percentage of protein binding,"The percentage of protein binding (about 44%, n = 3-7) did not change by increasing the serum concentration (8.2-24.6 micrograms/ml).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,44,63555,DB01223,Aminophylline
,18005375,in,"For theophylline, the concentration/time profiles after intraperitoneal and after intravenous administration were almost identical, and the intraperitoneal bioavailability was calculated to 0.94.","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.94,73530,DB01223,Aminophylline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.71,73531,DB01223,Aminophylline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.65,73532,DB01223,Aminophylline
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,5.11,74274,DB01223,Aminophylline
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.54,74275,DB01223,Aminophylline
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),,4.78,74276,DB01223,Aminophylline
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.94,74277,DB01223,Aminophylline
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.051,74447,DB01223,Aminophylline
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.035,74448,DB01223,Aminophylline
,6887346,half-life (t1/2),The mean plasma theophylline half-life (t1/2) following the single intravenous dose was 7.8 h and the mean apparent specific volume of distribution (V'd(area] was 0.46 1/kg.,Pharmacokinetic studies of theophylline in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),h,7.8,78818,DB01223,Aminophylline
,6887346,apparent specific volume of distribution (V'd(area],The mean plasma theophylline half-life (t1/2) following the single intravenous dose was 7.8 h and the mean apparent specific volume of distribution (V'd(area] was 0.46 1/kg.,Pharmacokinetic studies of theophylline in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),[1] / [kg],0.46,78819,DB01223,Aminophylline
,6887346,absorption half-life (t1/2ab),The absorption half-life (t1/2ab) was 0.5 h and the bioavailability was 96% following oral administration.,Pharmacokinetic studies of theophylline in cats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),h,0.5,78820,DB01223,Aminophylline
,6887346,bioavailability,The absorption half-life (t1/2ab) was 0.5 h and the bioavailability was 96% following oral administration.,Pharmacokinetic studies of theophylline in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),%,96,78821,DB01223,Aminophylline
,3371147,Half-life,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),h,6.6,80162,DB01223,Aminophylline
,3371147,plasma clearance,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),[l] / [h·kg],0.44,80163,DB01223,Aminophylline
,3371147,volume of distribution,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),[l] / [kg],4,80164,DB01223,Aminophylline
,8489790,steady-state (SS) 'peaks',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],10,81657,DB01223,Aminophylline
,8489790,SS 'troughs',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],7.7,81658,DB01223,Aminophylline
,697173,clearance,"Within 24 hours of admission, the mean clearance in our patients without congestive heart failure or pneumonia was 44.5 ml per hour per kg of body weight, 40 per cent less than the value on which the widely used 0.9 mg per kg per hour dosage is based.","Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697173/),[ml] / [h·kg],44.5,85504,DB01223,Aminophylline
,7333345,absolute bioavailability,The absolute bioavailability of Theolair Retard 250 mg was 110.9 +/- 20.8% (mean +/-SD).,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),%,110.9,88192,DB01223,Aminophylline
,7333345,rate constant,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.8,88193,DB01223,Aminophylline
,7333345,rate constants,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.2,88194,DB01223,Aminophylline
,7333345,rate constants,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.8,88195,DB01223,Aminophylline
,7333345,peak levels,The peak levels accounted for 7.9 +/- 2.2 mg . 1-1.,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),mg,7.9,88196,DB01223,Aminophylline
,7333345,steady state serum concentration,The optimal dosing interval to obtain an average steady state serum concentration of 12.5 mg .,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),mg,12.5,88197,DB01223,Aminophylline
,10590713,ka(h-1),"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.223,88930,DB01223,Aminophylline
,10590713,ke(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.047,88931,DB01223,Aminophylline
,10590713,ke(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.076,88932,DB01223,Aminophylline
,10590713,Vd(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),[1] / [kg],0.733,88933,DB01223,Aminophylline
,10590713,Vd(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),[1] / [kg],0.830,88934,DB01223,Aminophylline
,10590713,bioavailability,"The bioavailability is 0.732, and theophylline/aminophylline is 0.846.",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.732,88935,DB01223,Aminophylline
,10590713,bioavailability,"The bioavailability is 0.732, and theophylline/aminophylline is 0.846.",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.846,88936,DB01223,Aminophylline
,1797890,t 1/2 beta,The median t 1/2 beta was 18.8 h (range 5.8-25.5) compared to a normal value of 6 h.,Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,18.8,90686,DB01223,Aminophylline
,1797890,t 1/2 beta,The median t 1/2 beta was 18.8 h (range 5.8-25.5) compared to a normal value of 6 h.,Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,6,90687,DB01223,Aminophylline
,1797890,t 1/2 beta,"Due to this t 1/2 beta was 2.3 (2.0-2.7) h, which is 5 times the normal value of 0.55 h.",Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,2.3,90688,DB01223,Aminophylline
,1797890,t 1/2 beta,"Due to this t 1/2 beta was 2.3 (2.0-2.7) h, which is 5 times the normal value of 0.55 h.",Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,0.55,90689,DB01223,Aminophylline
,12542900,total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )),"In rats with renal failure, the plasma concentrations of theophylline were considerably lower and the resultant total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )) of theophylline was significantly smaller (2,200 vs 1,550 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],"2,200",91693,DB01223,Aminophylline
,12542900,total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )),"In rats with renal failure, the plasma concentrations of theophylline were considerably lower and the resultant total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )) of theophylline was significantly smaller (2,200 vs 1,550 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],"1,550",91694,DB01223,Aminophylline
,12542900,AUC(0-6 h),"In rats with renal failure, the plasma concentrations of 1,3-dimethyluric acid were considerably higher and the resultant AUC(0-6 h) of 1,3-dimethyluric acid was significantly greater (44.4 vs 456 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],44.4,91695,DB01223,Aminophylline
,12542900,AUC(0-6 h),"In rats with renal failure, the plasma concentrations of 1,3-dimethyluric acid were considerably higher and the resultant AUC(0-6 h) of 1,3-dimethyluric acid was significantly greater (44.4 vs 456 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],456,91696,DB01223,Aminophylline
,12542900,intrinsic,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],734,91697,DB01223,Aminophylline
,12542900,intrinsic,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],529,91698,DB01223,Aminophylline
,12542900,formation clearance,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],734,91699,DB01223,Aminophylline
,12542900,formation clearance,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],529,91700,DB01223,Aminophylline
,2122422,area under the curve (AUC infinity 0),"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],126.0,91982,DB01223,Aminophylline
,2122422,area under the curve (AUC infinity 0),"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],127.3,91983,DB01223,Aminophylline
,2122422,maximum concentration,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[μg] / [ml],3.80,91984,DB01223,Aminophylline
,2122422,maximum concentration,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[μg] / [ml],4.08,91985,DB01223,Aminophylline
,2122422,time to peak plasma level,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),h,13,91986,DB01223,Aminophylline
,2122422,time to peak plasma level,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),h,11,91987,DB01223,Aminophylline
,2122422,AUC infinity 0,Mean AUC infinity 0 for the intravenous phase (161.4 micrograms hr/ml) was significantly higher than the AUC for either oral study (p less than 0.05).,The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],161.4,91988,DB01223,Aminophylline
,2122422,bioavailability,The mean bioavailability was 81% for phase 1 and 80% for phase 2.,The influence of enteral feedings on sustained-release theophylline absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),%,81,91989,DB01223,Aminophylline
,2122422,bioavailability,The mean bioavailability was 81% for phase 1 and 80% for phase 2.,The influence of enteral feedings on sustained-release theophylline absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),%,80,91990,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.042,92105,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.016,92106,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.038,92107,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.054,92108,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.030,92109,DB01223,Aminophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.057,92110,DB01223,Aminophylline
,7140800,steady-state minimum concentration (Cmeas),"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],5.4 to 14.6,92111,DB01223,Aminophylline
,7140800,steady-state minimum concentration (Cmeas),"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],9.0,92112,DB01223,Aminophylline
,7140800,Cpred,"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],5.6 to 13.6,92113,DB01223,Aminophylline
,7140800,Cpred,"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],9.0,92114,DB01223,Aminophylline
over,1257607,peak plasma concentration,"Theophylline peak plasma concentration of over 170 ng/ml average was observed when 300 mg of caffeine, equivalent to 2-3 cups of coffee, was administered to humans.",The human metabolism of caffeine to theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257607/),[ng] / [ml],170,97595,DB01223,Aminophylline
,6734703,bioavailability,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),%,93,98316,DB01223,Aminophylline
,6734703,time to peak of the plasma concentration curve,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),h,7,98317,DB01223,Aminophylline
,6734703,mean residence time,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),h,14,98318,DB01223,Aminophylline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.2,104304,DB01223,Aminophylline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.3,104305,DB01223,Aminophylline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],11.6,104306,DB01223,Aminophylline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],14.6,104307,DB01223,Aminophylline
,3403868,Relative bioavailability,Relative bioavailability of theophylline suspension was 89% of that for the solution.,Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),%,89,104308,DB01223,Aminophylline
,9352762,maximum rate of metabolism (Vmax),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),[mg] / [h],71,104350,DB01223,Aminophylline
,9352762,Michaelis-Menten constant (Km),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),[mg] / [l],32.3,104351,DB01223,Aminophylline
,9352762,volume of distribution (Vd),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),l,46.9,104352,DB01223,Aminophylline
,790952,Near-steady-state serum concentrations,Near-steady-state serum concentrations in the therapeutic range of 8-20 mg/liter were found in 72% of the patients.,System for clinical pharmacokinetic monitoring of theophylline therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/790952/),[mg] / [l],8-20,106409,DB01223,Aminophylline
,1271155,clearance,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),[l] / [h·kg],0.100,107355,DB01223,Aminophylline
,1271155,kel,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),1/[h],0.49,107356,DB01223,Aminophylline
,1271155,betat1/2,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),h,3.38,107357,DB01223,Aminophylline
,1271155,alphat1/2,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),h,0.13,107358,DB01223,Aminophylline
,1271155,V1,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),[1] / [kg],0.25,107359,DB01223,Aminophylline
,1271155,steady-state plasma concentration,"Calculations based upon mean values of pharmacokinetic constants predict that a maintenance dose rate for aminophylline of 30 mg/kg/day, after a loading dose of 5.6 mg/kg, would rapidly achieve and maintain a mean steady-state plasma concentration of theophylline of 10 mg/1.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),mg,10,107360,DB01223,Aminophylline
,31529628,Systemic bioavailability,Systemic bioavailability of the MCT was 96.2 ± 32.9%.,"Pharmacokinetics of a modified, compounded theophylline product in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),%,96.2,109878,DB01223,Aminophylline
,31529628,times to maximum concentration,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,8.85,109879,DB01223,Aminophylline
,31529628,mean absorption time,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,6.95,109880,DB01223,Aminophylline
,31529628,terminal half-life,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,8.67,109881,DB01223,Aminophylline
,3244609,terminal plasma half-life,The terminal plasma half-life of theophylline following an i.v. dose was found to be approximately 24 hr.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),h,24,112664,DB01223,Aminophylline
,3244609,volume of distribution,"The volume of distribution, Vdext, and clearance following the i.v. dose were approximately 0.7 liter/kg and 0.023 liter/hr/kg, respectively.",The effect of food on the absorption of controlled-release theophylline in mini-swine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),[l] / [kg],0.7,112665,DB01223,Aminophylline
,3244609,clearance,"The volume of distribution, Vdext, and clearance following the i.v. dose were approximately 0.7 liter/kg and 0.023 liter/hr/kg, respectively.",The effect of food on the absorption of controlled-release theophylline in mini-swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),[l] / [h·kg],0.023,112666,DB01223,Aminophylline
,3244609,terminal half-life,The terminal half-life of theophylline following the administration of theophylline capsules under fasting conditions was 21 hr.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),h,21,112667,DB01223,Aminophylline
,3244609,bioavailability,The average bioavailability under fasting conditions was approximately 80% compared to the i.v. dose.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),%,80,112668,DB01223,Aminophylline
,10387953,AUC0-2 h,"The AUC0-2 h of a metabolite of theophylline, 1,3-dimethyluric acid, 1,3-DMU (62.3 versus 106 microg/min per ml), and the percentages of intravenous dose of theophylline excreted in 24-h urine as 1,3-DMU (12.4% versus 20.8%, expressed in terms of theophylline) decreased significantly in 2-AP-pretreated rats when compared with those in control rats.","Effect of a new chemoprotective agent, 2-(allylthio)pyrazine, on the pharmacokinetics of intravenous theophylline in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10387953/),[μg] / [min·ml],62.3,112678,DB01223,Aminophylline
,10387953,AUC0-2 h,"The AUC0-2 h of a metabolite of theophylline, 1,3-dimethyluric acid, 1,3-DMU (62.3 versus 106 microg/min per ml), and the percentages of intravenous dose of theophylline excreted in 24-h urine as 1,3-DMU (12.4% versus 20.8%, expressed in terms of theophylline) decreased significantly in 2-AP-pretreated rats when compared with those in control rats.","Effect of a new chemoprotective agent, 2-(allylthio)pyrazine, on the pharmacokinetics of intravenous theophylline in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10387953/),[μg] / [min·ml],106,112679,DB01223,Aminophylline
greater,3813276,T0,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],15,114183,DB01223,Aminophylline
,3813276,max,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),,44,114184,DB01223,Aminophylline
,3813276,T12,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10.5,114185,DB01223,Aminophylline
less,3813276,initial clearances,Theophylline was withdrawn in 6 patients with initial clearances less than 5 ml/kg/h (zero in 5 cases).,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[ml] / [h·kg],5,114186,DB01223,Aminophylline
,3813276,T48,T48 was within therapeutic values (10-20 mg/l) in 55 p. 100 of cases (21/38).,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10-20,114187,DB01223,Aminophylline
less,3813276,T48,Twelve patients had T48 less than 10 mg/l due to an increase in theophylline clearance (+ 80 p. 100 on average) related to improved right ventricular function in 7 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10,114188,DB01223,Aminophylline
greater,3813276,T48,In 5 patients T48 was greater than 20 mg/l (max = 27.5) due to a fall in clearance (average -47 p. 100) which could have been caused by administration of erythromycin in 1 case and by dose-dependent kinetics in 2 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],20,114189,DB01223,Aminophylline
,3813276,max,In 5 patients T48 was greater than 20 mg/l (max = 27.5) due to a fall in clearance (average -47 p. 100) which could have been caused by administration of erythromycin in 1 case and by dose-dependent kinetics in 2 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),,27.5,114190,DB01223,Aminophylline
,7223434,V1,"The shape of semilogarithmic plots of all measured plasma theophylline concentrations versus time was compatible with the use of an open 2-compartment pharmacokinetic model assuming first-order distribution and elimination processes, but in the comparison of the mean values of the pharmacokinetic parameters obtained after the administration of the low and the high theophylline dose, statistical analysis by Student's t-test showed beta and V1 to be significantly altered (low dose: beta = 0.00338 min.-1, V1 = 392 ml kg-a; high dose: beta = 0.00198 min.-1, V1 = 528 ml kg-1; P less than 0.05).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),kg-a·ml,392,115762,DB01223,Aminophylline
,7223434,V1,"The shape of semilogarithmic plots of all measured plasma theophylline concentrations versus time was compatible with the use of an open 2-compartment pharmacokinetic model assuming first-order distribution and elimination processes, but in the comparison of the mean values of the pharmacokinetic parameters obtained after the administration of the low and the high theophylline dose, statistical analysis by Student's t-test showed beta and V1 to be significantly altered (low dose: beta = 0.00338 min.-1, V1 = 392 ml kg-a; high dose: beta = 0.00198 min.-1, V1 = 528 ml kg-1; P less than 0.05).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[ml] / [kg],528,115763,DB01223,Aminophylline
,7223434,kel 3MX,"The administered 3-methylxanthine was eliminated unchanged with a first-order rate constant ten times larger than the total elimination rate constant of theophylline itself, the latter being observed after the administration of the equimolar dose of aminophylline (kel 3MX = 0.029 min.-1, kel theophylline = 0.00293 min.-1).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),-1·min,0.029,115764,DB01223,Aminophylline
,7223434,kel,"The administered 3-methylxanthine was eliminated unchanged with a first-order rate constant ten times larger than the total elimination rate constant of theophylline itself, the latter being observed after the administration of the equimolar dose of aminophylline (kel 3MX = 0.029 min.-1, kel theophylline = 0.00293 min.-1).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),-1·min,0.00293,115765,DB01223,Aminophylline
,7223434,Clearance,Clearance was calculated to 14.4 ml kg-1 min.-1 for 3-methylxanthine and 1.50 ml kg-1 min.-1 for theophylline.,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[-1·min·ml] / [kg],14.4,115766,DB01223,Aminophylline
,7223434,Clearance,Clearance was calculated to 14.4 ml kg-1 min.-1 for 3-methylxanthine and 1.50 ml kg-1 min.-1 for theophylline.,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[-1·min·ml] / [kg],1.50,115767,DB01223,Aminophylline
,3991030,bioavailability,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),,101.2,118902,DB01223,Aminophylline
,3991030,peak times,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),h,3.6,118903,DB01223,Aminophylline
,3991030,peak times,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),h,1.3,118904,DB01223,Aminophylline
,3991030,peak plasma concentrations,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),[mg] / [1·g·l],16.8,118905,DB01223,Aminophylline
,3991030,peak plasma concentrations,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),[mg] / [1·l],21.1,118906,DB01223,Aminophylline
,3449080,elimination half-life,It was shown that the elimination half-life of theophylline in Thai asthmatic children (average 7.21 hours) was longer than that observed for subjects in western countries.,Pharmacokinetics of oral theophylline in Thai asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),h,7.21,121350,DB01223,Aminophylline
,3449080,elimination half-lives,Variations in elimination half-lives ranging from 4.44 to 14.34 hours were intersubject variations.,Pharmacokinetics of oral theophylline in Thai asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),h,4.44 to 14.34,121351,DB01223,Aminophylline
,3449080,maximum,"Using data from this study, the predicted maximum and minimum serum theophylline concentrations at steady state were calculated to be 16.53 micrograms/ml and 9.96 micrograms/ml, respectively.",Pharmacokinetics of oral theophylline in Thai asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),[μg] / [ml],16.53,121352,DB01223,Aminophylline
,3449080,minimum serum theophylline concentrations at steady state,"Using data from this study, the predicted maximum and minimum serum theophylline concentrations at steady state were calculated to be 16.53 micrograms/ml and 9.96 micrograms/ml, respectively.",Pharmacokinetics of oral theophylline in Thai asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),[μg] / [ml],9.96,121353,DB01223,Aminophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,6.0,123270,DB01223,Aminophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,9.3,123271,DB01223,Aminophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,4.6,123272,DB01223,Aminophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,6.3,123273,DB01223,Aminophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(-1)1.73·(m)^2·min],43.8,123274,DB01223,Aminophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(m)^2·min],37.4,123275,DB01223,Aminophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[1.73·ml] / [(m)^2·min],64.2,123276,DB01223,Aminophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(m)^2·min],53.1,123277,DB01223,Aminophylline
,20193253,capsule activation time,The mean capsule activation time for the small bowel and ascending colon was 2.07 hours and 6.08 hours post dose.,Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),h,2.07,123660,DB01223,Aminophylline
,20193253,capsule activation time,The mean capsule activation time for the small bowel and ascending colon was 2.07 hours and 6.08 hours post dose.,Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),h,6.08,123661,DB01223,Aminophylline
,20193253,area under the curve (AUC(t)) ratio,"Aminophylline had similar absorption profiles from the small bowel compared with the stomach, with an area under the curve (AUC(t)) ratio of 92% vs. the stomach, but a lower absorption profile from the ascending colon, with an AUC(t) ratio of 47.2% vs. the stomach.",Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),%,92,123662,DB01223,Aminophylline
,20193253,AUC(t) ratio,"Aminophylline had similar absorption profiles from the small bowel compared with the stomach, with an area under the curve (AUC(t)) ratio of 92% vs. the stomach, but a lower absorption profile from the ascending colon, with an AUC(t) ratio of 47.2% vs. the stomach.",Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),%,47.2,123663,DB01223,Aminophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,99,126273,DB01223,Aminophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,102,126274,DB01223,Aminophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,103,126275,DB01223,Aminophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,98,126276,DB01223,Aminophylline
,23745275,plasma clearance,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),[ml] / [h·kg],17.88,126366,DB01223,Aminophylline
,23745275,apparent volume of distribution,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),[l] / [kg],0.93,126367,DB01223,Aminophylline
,23745275,half life time,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),h,28.6,126368,DB01223,Aminophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],16 to 28,126871,DB01223,Aminophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],7.4 to 14,126872,DB01223,Aminophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],18 to 26,126873,DB01223,Aminophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],260 to 335,126874,DB01223,Aminophylline
,3376182,half-life,Large ranges were found in the half-life (2.3-21.3 h) and calculated apparent volume of distribution (Vd) (0.300-1.54 L/kg).,A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),h,2.3-21.3,128229,DB01223,Aminophylline
,3376182,apparent volume of distribution (Vd),Large ranges were found in the half-life (2.3-21.3 h) and calculated apparent volume of distribution (Vd) (0.300-1.54 L/kg).,A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),[l] / [kg],0.300-1.54,128230,DB01223,Aminophylline
,3376182,Vd,"Vd values than with the standard Vd of 0.5 L/kg (r = 0.31, NS), and predictions obtained with the individuals'",A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),[l] / [kg],0.5,128231,DB01223,Aminophylline
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB01223,Aminophylline
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB01223,Aminophylline
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],8.5,131399,DB01223,Aminophylline
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],1.3,131400,DB01223,Aminophylline
,7446501,half-life,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),h,4.7,131473,DB01223,Aminophylline
,7446501,total clearance,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),[ml] / [h·kg],91,131474,DB01223,Aminophylline
,7446501,volume of distribution,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),[ml] / [kg],574,131475,DB01223,Aminophylline
,10434239,steady-state concentration,This was a concentration-controlled drug interaction study in which the subjects were administered a dose of SR theophylline every 12 hours to provide a mean steady-state concentration between 8 and 15 micrograms/ml.,The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434239/),[μg] / [ml],8 and 15,131955,DB01223,Aminophylline
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.5,133072,DB01223,Aminophylline
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.3,133073,DB01223,Aminophylline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],12.6,135521,DB01223,Aminophylline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],13.1,135522,DB01223,Aminophylline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.0,135523,DB01223,Aminophylline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],7.9,135524,DB01223,Aminophylline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.6,135525,DB01223,Aminophylline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],8.0,135526,DB01223,Aminophylline
,4019794,Cmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[μg] / [ml],6.7,141426,DB01223,Aminophylline
,4019794,Cmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[μg] / [ml],5.4,141427,DB01223,Aminophylline
,4019794,tmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),h,2,141428,DB01223,Aminophylline
,4019794,F8h,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),,0.79,141429,DB01223,Aminophylline
,4019794,F8h,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),,0.83,141430,DB01223,Aminophylline
,4019794,release rate,"The in vitro release rate of theophylline from freshly prepared formulations was, however, higher (4.8 mg min-1) from aminophylline suppositories relative to those containing theophylline (2.9 mg min-1).",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],4.8,141431,DB01223,Aminophylline
,4019794,release rate,"The in vitro release rate of theophylline from freshly prepared formulations was, however, higher (4.8 mg min-1) from aminophylline suppositories relative to those containing theophylline (2.9 mg min-1).",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],2.9,141432,DB01223,Aminophylline
,4019794,release rate,The release rate of aminophylline suppositories tested after 1-year storage at room temperature dropped from 4.8 to 0.5 mg min-1.,Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],4.8,141433,DB01223,Aminophylline
,4019794,release rate,The release rate of aminophylline suppositories tested after 1-year storage at room temperature dropped from 4.8 to 0.5 mg min-1.,Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],0.5,141434,DB01223,Aminophylline
,2287562,hepatic blood flow,Estimated hepatic blood flow decreased from 790 +/- 190 to 665 +/- 100 ml/minute (p less than 0.05) after administration of aminophylline.,The effect of theophylline on estimated hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287562/),[ml] / [min],790,143450,DB01223,Aminophylline
,2287562,hepatic blood flow,Estimated hepatic blood flow decreased from 790 +/- 190 to 665 +/- 100 ml/minute (p less than 0.05) after administration of aminophylline.,The effect of theophylline on estimated hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287562/),[ml] / [min],665,143451,DB01223,Aminophylline
,434904,Apparent volume of distribution,Apparent volume of distribution of theophylline in 12 infants was 0.71 +/- 0.18 1/kg (mean +/- SD).,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[1] / [kg],0.71,143893,DB01223,Aminophylline
,434904,Plasma clearance rate,Plasma clearance rate measured in 11 infants at steady state was 18.6 +/- 4.8 ml/kg per hour.,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[ml] / [h·kg],18.6,143894,DB01223,Aminophylline
,3428347,infusion rate,A reduction in the infusion rate from 69 to 33 mg.h-1 was made in Study 2 after 8 h in order to mimic the concentration/time profile of the oral formulation as closely as possible.,Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),[mg] / [h],69,146406,DB01223,Aminophylline
,3428347,infusion rate,A reduction in the infusion rate from 69 to 33 mg.h-1 was made in Study 2 after 8 h in order to mimic the concentration/time profile of the oral formulation as closely as possible.,Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),[mg] / [h],33,146407,DB01223,Aminophylline
,3428347,absolute bioavailability,"The absolute bioavailability was 100 (89, 115)% in Study 1 and 88 (73, 105)% in Study 2.",Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),%,100,146408,DB01223,Aminophylline
,3428347,absolute bioavailability,"The absolute bioavailability was 100 (89, 115)% in Study 1 and 88 (73, 105)% in Study 2.",Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),%,88,146409,DB01223,Aminophylline
,7140801,Peak serum concentrations,Peak serum concentrations of theophylline measured by HPLC ranged from 8.48-21.6 micrograms/ml.,Pharmacokinetics of theophylline in infants with bronchiolitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[μg] / [ml],8.48-21.6,146538,DB01223,Aminophylline
,7140801,Total,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],4.66 to 19.25,146539,DB01223,Aminophylline
,7140801,renal,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],1.07 to 5.76,146540,DB01223,Aminophylline
,7140801,nonrenal clearance,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],1.07 to 5.76,146541,DB01223,Aminophylline
,7140801,nonrenal clearance,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],3.59 to 16.83,146542,DB01223,Aminophylline
,7140801,apparent volume of distribution,"Mean apparent volume of distribution and elimination half-life were 8.75 l/m2 and 11.38 h, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[l] / [m2],8.75,146543,DB01223,Aminophylline
,7140801,elimination half-life,"Mean apparent volume of distribution and elimination half-life were 8.75 l/m2 and 11.38 h, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),h,11.38,146544,DB01223,Aminophylline
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],0.88,147237,DB01223,Aminophylline
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],1.21,147238,DB01223,Aminophylline
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.104,147239,DB01223,Aminophylline
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.148,147240,DB01223,Aminophylline
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],104,147241,DB01223,Aminophylline
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],76,147242,DB01223,Aminophylline
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,7.0,147243,DB01223,Aminophylline
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,4.8,147244,DB01223,Aminophylline
,4091990,trough concentrations,"After repeated 12-hourly dosing to steady-state, and adjustment of dose to achieve trough concentrations of between 5 and 10 mg l-1 (28-55 mumol l-1), theophylline concentration fluctuated to a significantly greater extent within a dose interval when the subjects were taking Phyllocontin than when they were taking Theo-Dur.",The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091990/),[mg] / [l],5 and 10,151207,DB01223,Aminophylline
,4091990,trough concentrations,"After repeated 12-hourly dosing to steady-state, and adjustment of dose to achieve trough concentrations of between 5 and 10 mg l-1 (28-55 mumol l-1), theophylline concentration fluctuated to a significantly greater extent within a dose interval when the subjects were taking Phyllocontin than when they were taking Theo-Dur.",The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091990/),[μM] / [l],28-55,151208,DB01223,Aminophylline
,2715932,V (L),"Volume of distribution in this population was adequately described using only weight, with V (L) = 0.858 L/kg.",The population pharmacokinetics of theophylline in neonates and young infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715932/),[l] / [kg],0.858,151427,DB01223,Aminophylline
,12534637,rate,Retrospective data were collected from 75 term neonates and children (age range 2 days to 17 years) receiving continuous infusions of aminophylline (mean rate 9.2 +/- 2.6 micro g kg-1 min-1) during ECMO.,Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534637/),μ,9.2,151483,DB01223,Aminophylline
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],26,153843,DB01223,Aminophylline
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],19,153844,DB01223,Aminophylline
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],21.2,153845,DB01223,Aminophylline
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],14.9,153846,DB01223,Aminophylline
,28108402,Cmax,"PBPK modelling of a 5 mg/kg iv loading dose (≤18yr) shows a mean Cmax of 8.99 mg/L (5th-95th centiles 5.5-13.7 mg/L), with 70.3% of subjects <10 mg/L, 29.4% achieving 10-20 mg/L, and 0.1% > 20 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],8.99,156698,DB01223,Aminophylline
,28108402,steady state infusion concentration,"For an aminophylline infusion (0-12 y) of 1.0 mg/kg/h, the mean steady state infusion concentration was 16.4 mg/L, (5th-95th centiles 5.3-32 mg/L), with 26.8% having a serum concentration >20 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],16.4,156699,DB01223,Aminophylline
,28108402,steady state infusion concentration,"For 12-18yr receiving 0.5 mg/kg/h infusion, the mean steady state infusion concentration was 9.37 mg/L (5th-95th centiles 3.4-18 mg/L), with 59.8% having a serum concentration <10 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],9.37,156700,DB01223,Aminophylline
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],12.1,157653,DB01223,Aminophylline
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],8,157654,DB01223,Aminophylline
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],18,157655,DB01223,Aminophylline
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],11,157656,DB01223,Aminophylline
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],253,157657,DB01223,Aminophylline
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],249,157658,DB01223,Aminophylline
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],10,157659,DB01223,Aminophylline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.44,158191,DB01223,Aminophylline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.42,158192,DB01223,Aminophylline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.82,158193,DB01223,Aminophylline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.73,158194,DB01223,Aminophylline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.27,158195,DB01223,Aminophylline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.72,158196,DB01223,Aminophylline
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,4.5,159420,DB01223,Aminophylline
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,134.5,159421,DB01223,Aminophylline
,2305422,peak level,The mean extrapolated peak level was 8.5 +/- 0.9 mg/L.,Theophylline pharmacokinetics in black Zimbabwean males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[mg] / [l],8.5,159566,DB01223,Aminophylline
,2305422,half-life,"The mean half-life and volume of distribution were 10.1 +/- 3.1 h and 0.55 +/- 0.7 L/kg, respectively.",Theophylline pharmacokinetics in black Zimbabwean males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),h,10.1,159567,DB01223,Aminophylline
,2305422,volume of distribution,"The mean half-life and volume of distribution were 10.1 +/- 3.1 h and 0.55 +/- 0.7 L/kg, respectively.",Theophylline pharmacokinetics in black Zimbabwean males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[l] / [kg],0.55,159568,DB01223,Aminophylline
,2305422,clearance,The mean clearance was 0.62 +/- 0.17 ml/kg/min.,Theophylline pharmacokinetics in black Zimbabwean males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[ml] / [kg·min],0.62,159569,DB01223,Aminophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],9.8,160466,DB01223,Aminophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],10.3,160467,DB01223,Aminophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],10.8,160468,DB01223,Aminophylline
,276563,total,The mean total theophylline clearance rate was 1.32 +/- S.D. 0.66 ml/min/kg.,Pharmacokinetics of theophylline in acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/276563/),[ml] / [kg·min],1.32,160880,DB01223,Aminophylline
,758787,clearances,"Serum theophylline concentrations ranged from 5.1 microgram/ml to 20.1 microgram/ml, and clearances ranged from 0.03 liter/kg/hr to 0.09 liter/kg/hr.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[l] / [h·kg],0.03,162715,DB01223,Aminophylline
,758787,clearances,"Serum theophylline concentrations ranged from 5.1 microgram/ml to 20.1 microgram/ml, and clearances ranged from 0.03 liter/kg/hr to 0.09 liter/kg/hr.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[l] / [h·kg],0.09,162716,DB01223,Aminophylline
,758787,maximum concentration,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],10.4,162717,DB01223,Aminophylline
,758787,maximum concentration,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],23.8,162718,DB01223,Aminophylline
,758787,minimum,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],6.5,162719,DB01223,Aminophylline
,758787,minimum,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],15.2,162720,DB01223,Aminophylline
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],23.6,163548,DB01223,Aminophylline
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],19.6,163549,DB01223,Aminophylline
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.23,163550,DB01223,Aminophylline
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.19,163551,DB01223,Aminophylline
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.04,163552,DB01223,Aminophylline
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.66,163553,DB01223,Aminophylline
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.26,163554,DB01223,Aminophylline
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.23,163555,DB01223,Aminophylline
,12570924,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[min·μg] / [ml],"1,040",165236,DB01223,Aminophylline
,12570924,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[min·μg] / [ml],"1,750",165237,DB01223,Aminophylline
,12570924,renal clearance (CL(R),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],1.39,165238,DB01223,Aminophylline
,12570924,renal clearance (CL(R),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],0.571,165239,DB01223,Aminophylline
,12570924,nonrenal clearance (CL(NR),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],3.36,165240,DB01223,Aminophylline
,12570924,nonrenal clearance (CL(NR),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],2.25,165241,DB01223,Aminophylline
,12570924,intrinsic,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],267,165242,DB01223,Aminophylline
,12570924,formation clearance,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],267,165243,DB01223,Aminophylline
,12570924,formation clearance,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],180 x 10(-6),165244,DB01223,Aminophylline
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,6.3,165985,DB01223,Aminophylline
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.2,165986,DB01223,Aminophylline
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.5,165987,DB01223,Aminophylline
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.6,165988,DB01223,Aminophylline
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],4 to 8,167513,DB01223,Aminophylline
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],3.6 to 11.5,167514,DB01223,Aminophylline
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5,167515,DB01223,Aminophylline
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5.2 to 8.9,167516,DB01223,Aminophylline
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],79.9,167517,DB01223,Aminophylline
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167518,DB01223,Aminophylline
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],40.9,167519,DB01223,Aminophylline
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167520,DB01223,Aminophylline
,32040456,Cmax,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [l],42.4,167880,DB01223,Aminophylline
,32040456,Cmax,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [l],19.0,167881,DB01223,Aminophylline
,32040456,AUC0→∞,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [h·l],84.9,167882,DB01223,Aminophylline
,32040456,AUC0→∞,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [h·l],41.4,167883,DB01223,Aminophylline
,32040456,Ke,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),1/[h],0.12,167884,DB01223,Aminophylline
,32040456,Ke,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),1/[h],0.24,167885,DB01223,Aminophylline
,32040456,t1/2,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),h,5.87,167886,DB01223,Aminophylline
,32040456,t1/2,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),h,2.88,167887,DB01223,Aminophylline
,3712142,first,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168092,DB01223,Aminophylline
,3712142,second,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168093,DB01223,Aminophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168094,DB01223,Aminophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],69.7,168095,DB01223,Aminophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],84.1,168096,DB01223,Aminophylline
,7378114,absorption rate,"After the administration of 350 mg a retard preparation of theophylline-ethylenediamine (Aminophyllin retard) p.o. to 10 healthy test persons the absorption rate of theophylline amounted to an average of 84%, after which the absorption had not been fully completed in all persons after 10 h.",[Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378114/),%,84,168385,DB01223,Aminophylline
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.1,169892,DB01223,Aminophylline
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.7,169893,DB01223,Aminophylline
,2350534,clearance,The mean clearance of theophylline was significantly lowered after INH (2.20 +/- 0.24 l h-1) (mean +/- s.e. mean) compared with the baseline value (2.80 +/- 0.24 l h-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [h],2.20,170839,DB01223,Aminophylline
,2350534,clearance,The mean clearance of theophylline was significantly lowered after INH (2.20 +/- 0.24 l h-1) (mean +/- s.e. mean) compared with the baseline value (2.80 +/- 0.24 l h-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [h],2.80,170840,DB01223,Aminophylline
,2350534,volume of distribution at steady state,The volume of distribution at steady state was also lowered significantly after INH (0.42 +/- 0.01 l kg-1 vs 0.47 +/- 0.02 l kg-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [kg],0.42,170841,DB01223,Aminophylline
,2350534,volume of distribution at steady state,The volume of distribution at steady state was also lowered significantly after INH (0.42 +/- 0.01 l kg-1 vs 0.47 +/- 0.02 l kg-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [kg],0.47,170842,DB01223,Aminophylline
,2350534,half-life,"Consequently, there was no significant prolongation of theophylline half-life after INH (7.0 +/- 0.3 h vs 6.7 +/- 0.4 h control).",Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),h,7.0,170843,DB01223,Aminophylline
,2350534,half-life,"Consequently, there was no significant prolongation of theophylline half-life after INH (7.0 +/- 0.3 h vs 6.7 +/- 0.4 h control).",Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),h,6.7,170844,DB01223,Aminophylline
,15074856,plasma terminal half-life,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),h,8.4,171278,DB01223,Aminophylline
,15074856,volume of distribution,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),[l] / [kg],0.546,171279,DB01223,Aminophylline
,15074856,systemic clearance,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),[min(1·ml] / [kg],0.780,171280,DB01223,Aminophylline
>,15074856,Systemic availability,Systemic availability was > 80% for both oral formulations.,Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),%,80,171281,DB01223,Aminophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.57,172222,DB01223,Aminophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.61,172223,DB01223,Aminophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.63,172224,DB01223,Aminophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.62,172225,DB01223,Aminophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,7.9,172226,DB01223,Aminophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,9.2,172227,DB01223,Aminophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,10.3,172228,DB01223,Aminophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,8.6,172229,DB01223,Aminophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.90,172230,DB01223,Aminophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.84,172231,DB01223,Aminophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.78,172232,DB01223,Aminophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.89,172233,DB01223,Aminophylline
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.85,172631,DB01223,Aminophylline
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.56,172632,DB01223,Aminophylline
,2746720,mean residence time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,19.4,174292,DB01223,Aminophylline
,2746720,mean residence time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,15.8,174293,DB01223,Aminophylline
,2746720,mean absorption time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,8.0,174294,DB01223,Aminophylline
,2746720,mean absorption time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,4.8,174295,DB01223,Aminophylline
,2746720,absolute bioavailability,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),%,82,174296,DB01223,Aminophylline
,2746720,absolute bioavailability,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),%,76,174297,DB01223,Aminophylline
,2746720,time to peak plasma concentrations,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,8,174298,DB01223,Aminophylline
,2746720,peak plasma concentrations,"After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 +/- 3.4 micrograms/ml; TD = 14.3 +/- 6.7 micrograms/ml).",Sustained-release theophylline pharmacokinetics in the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),[μg] / [ml],10.5,174299,DB01223,Aminophylline
,2746720,peak plasma concentrations,"After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 +/- 3.4 micrograms/ml; TD = 14.3 +/- 6.7 micrograms/ml).",Sustained-release theophylline pharmacokinetics in the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),[μg] / [ml],14.3,174300,DB01223,Aminophylline
,711929,clearance rate,"The mean clearance rate was 1.07 +/- 0.55 ml/min-kg, which is comparable with values obtained by others in older children.",Pharmacokinetics of theophylline in infancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711929/),[ml] / [min-kg],1.07,174792,DB01223,Aminophylline
,711929,half-life,The mean half-life was 4.4 +/- 2.2 hours.,Pharmacokinetics of theophylline in infancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711929/),h,4.4,174793,DB01223,Aminophylline
,7086267,t1/2,"The t1/2 of theophylline in the newborn rabbit was 43.5 +/- 12.0 hr, approximately 15 times longer than in the nonpregnant rabbit.",Theophylline elimination in the pregnant and fetal rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086267/),h,43.5,175177,DB01223,Aminophylline
,6829982,T1/2,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),h,4.45,175878,DB01223,Aminophylline
,6829982,Vd,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),[ml] / [kg],505.8,175879,DB01223,Aminophylline
,6829982,Cl,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),[ml] / [h·kg],87.9,175880,DB01223,Aminophylline
,6829982,F,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),,0.86,175881,DB01223,Aminophylline
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.39,180088,DB01223,Aminophylline
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.23,180089,DB01223,Aminophylline
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.171,180090,DB01223,Aminophylline
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.155,180091,DB01223,Aminophylline
,36261,initial drug clearance,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),[l] / [h·kg],0.77,181177,DB01223,Aminophylline
,36261,half-life,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),h,9.1,181178,DB01223,Aminophylline
,36261,apparent volume of drug distribution,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),[l] / [kg],.887,181179,DB01223,Aminophylline
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB01223,Aminophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB01223,Aminophylline
,6680648,volume distribution,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),[ml] / [kg],573,186099,DB01223,Aminophylline
,6680648,clearance rate,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),[ml] / [kg·min],.88,186100,DB01223,Aminophylline
,6680648,half-life,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),h,7.95,186101,DB01223,Aminophylline
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,76,189383,DB01223,Aminophylline
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,71,189384,DB01223,Aminophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],15.3,189466,DB01223,Aminophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],4.9,189467,DB01223,Aminophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],2.5,189468,DB01223,Aminophylline
,6512916,half-life,A rapid distributive phase with a half-life of approximately 15-30 min was followed by a slower elimination half-life averaging 15-17 h.,Pharmacokinetics and bioavailability of theophylline in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),min,15-30,189496,DB01223,Aminophylline
,6512916,elimination half-life,A rapid distributive phase with a half-life of approximately 15-30 min was followed by a slower elimination half-life averaging 15-17 h.,Pharmacokinetics and bioavailability of theophylline in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),h,15-17,189497,DB01223,Aminophylline
,6512916,apparent volume of distribution,The apparent volume of distribution averaged 850-900 ml/kg.,Pharmacokinetics and bioavailability of theophylline in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),[ml] / [kg],850-900,189498,DB01223,Aminophylline
,2622858,total plasma theophylline clearance,The total plasma theophylline clearance in dogs following an i.v. dose was 0.128 liter/hr/kg and the volume of distribution was 0.8 liter/kg using a one-compartment model.,The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),[l] / [h·kg],0.128,190453,DB01223,Aminophylline
,2622858,volume of distribution,The total plasma theophylline clearance in dogs following an i.v. dose was 0.128 liter/hr/kg and the volume of distribution was 0.8 liter/kg using a one-compartment model.,The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),[l] / [kg],0.8,190454,DB01223,Aminophylline
,2622858,absolute bioavailabilities,"The absolute bioavailabilities of these two products under fasting conditions were 31 and 48%, respectively.",The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),%,31,190455,DB01223,Aminophylline
,2622858,absolute bioavailabilities,"The absolute bioavailabilities of these two products under fasting conditions were 31 and 48%, respectively.",The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),%,48,190456,DB01223,Aminophylline
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],1.73,190591,DB01223,Aminophylline
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],0.94,190592,DB01223,Aminophylline
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],76.19,190593,DB01223,Aminophylline
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],52.66,190594,DB01223,Aminophylline
,7649598,Tmax,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,5.60,190595,DB01223,Aminophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,16.80,190596,DB01223,Aminophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,44.88,190597,DB01223,Aminophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,125.07,190598,DB01223,Aminophylline
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],2.19,190599,DB01223,Aminophylline
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],3.85,190600,DB01223,Aminophylline
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],34.07,190601,DB01223,Aminophylline
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],25.26,190602,DB01223,Aminophylline
,27995649,Total,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.50,190647,DB01223,Aminophylline
,27995649,renal,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.16,190648,DB01223,Aminophylline
,27995649,nonrenal clearances,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.34,190649,DB01223,Aminophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,6.3,190993,DB01223,Aminophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,5.3,190994,DB01223,Aminophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,4.9,190995,DB01223,Aminophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],88.9,190996,DB01223,Aminophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],75.4,190997,DB01223,Aminophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,4.9,190998,DB01223,Aminophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],67.7,190999,DB01223,Aminophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],12.0,192614,DB01223,Aminophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],22.5,192615,DB01223,Aminophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],22.6,192616,DB01223,Aminophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],5,192617,DB01223,Aminophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],13,192618,DB01223,Aminophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],34,192619,DB01223,Aminophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],2.7,192620,DB01223,Aminophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],9.3,192621,DB01223,Aminophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],14.2,192622,DB01223,Aminophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],2.7,192623,DB01223,Aminophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],9.3,192624,DB01223,Aminophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],14.2,192625,DB01223,Aminophylline
,7023306,apparent volume of distribution,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194021,DB01223,Aminophylline
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194022,DB01223,Aminophylline
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.053,194023,DB01223,Aminophylline
,6500770,maximum concentration,"The maximum concentration was found after 5.2 +/- 0.6 h (mean +/- S.D.) and 5.3 +/- 2.2 h and measured 2.00 +/- 0.28 mg.1-1 and 2.46 +/- 0.60 mg.1-1, respectively.","The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),mg,2.00,196567,DB01223,Aminophylline
,6500770,maximum concentration,"The maximum concentration was found after 5.2 +/- 0.6 h (mean +/- S.D.) and 5.3 +/- 2.2 h and measured 2.00 +/- 0.28 mg.1-1 and 2.46 +/- 0.60 mg.1-1, respectively.","The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),mg,2.46,196568,DB01223,Aminophylline
,6500770,absolute bioavailability,The absolute bioavailability of the whole tablets was 91.8 +/- 24.7% and that of the broken tablets was 95.8 +/- 9.7%.,"The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),%,91.8,196569,DB01223,Aminophylline
,6500770,absolute bioavailability,The absolute bioavailability of the whole tablets was 91.8 +/- 24.7% and that of the broken tablets was 95.8 +/- 9.7%.,"The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),%,95.8,196570,DB01223,Aminophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],18.8,197526,DB01223,Aminophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],53.7,197527,DB01223,Aminophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],63.0,197528,DB01223,Aminophylline
,648214,half-life,The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28.8 +/- 14.3 hours compared to 6.0 +/- 2.1 hours in normal subjects.,Pharmacokinetics of theophylline in hepatic disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),h,28.8,197529,DB01223,Aminophylline
,648214,half-life,The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28.8 +/- 14.3 hours compared to 6.0 +/- 2.1 hours in normal subjects.,Pharmacokinetics of theophylline in hepatic disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),h,6.0,197530,DB01223,Aminophylline
,6846940,clearance,Erythromycin significantly decreased mean theophylline clearance by 22% from 4.9 L/min to 3.87 L/min (p less than 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[l] / [min],4.9,198915,DB01223,Aminophylline
,6846940,clearance,Erythromycin significantly decreased mean theophylline clearance by 22% from 4.9 L/min to 3.87 L/min (p less than 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[l] / [min],3.87,198916,DB01223,Aminophylline
,6846940,peak theophylline levels,Mean peak theophylline levels increased 28% from 11.9 micrograms/ml to 15.3 micrograms/ml (p = 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[μg] / [ml],11.9,198917,DB01223,Aminophylline
,6846940,peak theophylline levels,Mean peak theophylline levels increased 28% from 11.9 micrograms/ml to 15.3 micrograms/ml (p = 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[μg] / [ml],15.3,198918,DB01223,Aminophylline
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.83,200056,DB01223,Aminophylline
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.73,200057,DB01223,Aminophylline
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,7.1,200058,DB01223,Aminophylline
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,8.1,200059,DB01223,Aminophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.4,200972,DB01223,Aminophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200973,DB01223,Aminophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200974,DB01223,Aminophylline
,27071281,recovery,The applied analitycal method showed excellent recovery (94.65%).,Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27071281/),%,94.65,201137,DB01223,Aminophylline
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],10.9,205057,DB01223,Aminophylline
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],15.9,205058,DB01223,Aminophylline
,7862714,ED50,"Chronic treatment with AMPH resulted in further increase of ED50 of DZP, which was 20.2 mg/kg, and this elevation was significant not only when compared with saline-treated animals, but also with acute and 3-day administration of the xanthine (p < 0.01, 0.05, and 0.001, respectively).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],20.2,205059,DB01223,Aminophylline
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],218,205060,DB01223,Aminophylline
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],252,205061,DB01223,Aminophylline
,1554321,volume of distribution,The volume of distribution of theophylline was 0.572 +/- 0.076 L/kg during and attack while it was 0.458 +/- 0.116 L/kg during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[l] / [kg],0.572,205366,DB01223,Aminophylline
,1554321,volume of distribution,The volume of distribution of theophylline was 0.572 +/- 0.076 L/kg during and attack while it was 0.458 +/- 0.116 L/kg during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[l] / [kg],0.458,205367,DB01223,Aminophylline
,1554321,half-life,The half-life of theophylline was 7.741 +/- 3.313 hr. during an attack while its was 4.710 +/- 1.873 hr. during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),h,7.741,205368,DB01223,Aminophylline
,1554321,half-life,The half-life of theophylline was 7.741 +/- 3.313 hr. during an attack while its was 4.710 +/- 1.873 hr. during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),h,4.710,205369,DB01223,Aminophylline
,1554321,clearance,The clearance of theophylline was 57.4 +/- 20.9 ml/kg/hr.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[ml] / [h·kg],57.4,205370,DB01223,Aminophylline
,22702215,clearance,Theophylline clearance was 0.064 +/- 0.017 liters/kg/hr in the non-pyrexia group and 0.049 +/- 0.010 liters/kg/hr in the pyrexia group.,Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.064,205782,DB01223,Aminophylline
,22702215,clearance,Theophylline clearance was 0.064 +/- 0.017 liters/kg/hr in the non-pyrexia group and 0.049 +/- 0.010 liters/kg/hr in the pyrexia group.,Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.049,205783,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.044,205784,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.030,205785,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.071,205786,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.047,205787,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.084,205788,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.055,205789,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.065,205790,DB01223,Aminophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.051,205791,DB01223,Aminophylline
,7418716,half-life of absorption,The half-life of absorption was 19 +/- 9 min (mean +/- SD).,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),min,19,207843,DB01223,Aminophylline
,7418716,Maximal serum concentrations,Maximal serum concentrations reached after 100 +/- 30 min were found to be in a rather narrow range: 9.8 +/- 2.5 mg x 1(-1).,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),mg,9.8,207844,DB01223,Aminophylline
,7418716,absolute bioavailability,The absolute bioavailability of the microcrystalline preparation was high and it showed only small variation: 102.7 +/- 10.2% of the dose.,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),%,102.7,207845,DB01223,Aminophylline
,972795,total clearance,The average total clearance of theophylline was 87 ml/hr/kg in the children and 57 ml/hr/kg in the adults.,Pharmacokinetics of theophylline in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),[ml] / [h·kg],87,208608,DB01223,Aminophylline
,972795,total clearance,The average total clearance of theophylline was 87 ml/hr/kg in the children and 57 ml/hr/kg in the adults.,Pharmacokinetics of theophylline in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),[ml] / [h·kg],57,208609,DB01223,Aminophylline
,972795,biologic half-life,"The biologic half-life of theophylline in the children ranged from 1.42 to 7.85 hours, reflecting mainly pronounced interindividual differences in the elimination rate constant of the drug.",Pharmacokinetics of theophylline in children with asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),h,1.42 to 7.85,208610,DB01223,Aminophylline
,4083583,half-life,"In the 6 horses, total body elimination rate constants were variable, and the half-life of theophylline was 9.7 to 19.3 hours.",Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,9.7 to 19.3,208976,DB01223,Aminophylline
,4083583,Clearance,Clearance was 42.3 to 69.2 ml/hr/kg.,Theophylline and dyphylline pharmacokinetics in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[ml] / [h·kg],42.3 to 69.2,208977,DB01223,Aminophylline
,4083583,t1/2,The initial distribution phase was rapid (t1/2 approx 3.5 to 4 minutes); a 2nd distribution phase was slower (t1/2 approx 1.5 to 2 hours).,Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),min,3.5 to 4,208978,DB01223,Aminophylline
,4083583,t1/2,The initial distribution phase was rapid (t1/2 approx 3.5 to 4 minutes); a 2nd distribution phase was slower (t1/2 approx 1.5 to 2 hours).,Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,1.5 to 2,208979,DB01223,Aminophylline
,4083583,apparent volume of distribution,The mean apparent volume of distribution was 1.02 L/kg.,Theophylline and dyphylline pharmacokinetics in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[l] / [kg],1.02,208980,DB01223,Aminophylline
,4083583,elimination half-life,"In the 6 horses, elimination half-life of dyphylline was 1.9 to 2.9 hours, and clearance was 200 to 320 ml/hr/kg.",Theophylline and dyphylline pharmacokinetics in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,1.9 to 2.9,208981,DB01223,Aminophylline
,4083583,clearance,"In the 6 horses, elimination half-life of dyphylline was 1.9 to 2.9 hours, and clearance was 200 to 320 ml/hr/kg.",Theophylline and dyphylline pharmacokinetics in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[ml] / [h·kg],200 to 320,208982,DB01223,Aminophylline
,4083583,Plasma concentrations,Plasma concentrations (approx 50 micrograms/ml) were observed at 10 minutes after injection without adverse effects.,Theophylline and dyphylline pharmacokinetics in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[μg] / [ml],50,208983,DB01223,Aminophylline
,2754145,bioavailability,"These include (1) a 16-year-old girl with consistent temporal fluctuation in STCs during administration of a sustained-release formulation every 8 hours because of delayed absorption and enhanced elimination of theophylline at night, (2) a 13-year-old girl with markedly delayed absorption of a once-daily preparation administered in the evening, (3) a 5-year-old boy with erratic absorption of a liquid theophylline preparation with significantly increased STCs during the night, and (4) a 49-year-old man with 60% bioavailability of aminophylline tablets.","Are theophylline ""levels"" a reliable indicator of compliance? ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754145/),%,60,210237,DB01223,Aminophylline
,1424911,Clearance,"Clearance of theophylline by hemodialysis was 119 ml/min, and the extraction efficiency was 0.56.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),[ml] / [min],119,210722,DB01223,Aminophylline
,1424911,extraction efficiency,"Clearance of theophylline by hemodialysis was 119 ml/min, and the extraction efficiency was 0.56.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),,0.56,210723,DB01223,Aminophylline
,1424911,elimination half-life,The elimination half-life of theophylline shortened from 5.7 h to 1.6 h during hemodialysis.,Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),h,5.7,210724,DB01223,Aminophylline
,1424911,elimination half-life,The elimination half-life of theophylline shortened from 5.7 h to 1.6 h during hemodialysis.,Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),h,1.6,210725,DB01223,Aminophylline
,1424911,rate constant (Kd),"The dialysis rate constant (Kd) was 0.32/h, and 79 percent of the total body store of the drug was removed during a 4-h dialysis.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),1/[h],0.32,210726,DB01223,Aminophylline
,2735986,peak flow rate (PFR),"Baseline peak flow rate (PFR) was significantly (P less than .03) higher in group 1 (170 +/- 85 L/min) than in group 2 (132 +/- 62 L/min), but did not differ significantly at any other times throughout the study.",Computer-assisted optimization of aminophylline therapy in the emergency department. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735986/),[l] / [min],170,210734,DB01223,Aminophylline
,2735986,peak flow rate (PFR),"Baseline peak flow rate (PFR) was significantly (P less than .03) higher in group 1 (170 +/- 85 L/min) than in group 2 (132 +/- 62 L/min), but did not differ significantly at any other times throughout the study.",Computer-assisted optimization of aminophylline therapy in the emergency department. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735986/),[l] / [min],132,210735,DB01223,Aminophylline
,6686557,bioavailability,"In 4 of the patients, mean bioavailability of the fourth dose was 38.9 +/- 8.4% and that of the sixth dose was 67.9 +/- 25.9% (p less than 0.05) in the other ten patients.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),%,38.9,210931,DB01223,Aminophylline
,6686557,bioavailability,"In 4 of the patients, mean bioavailability of the fourth dose was 38.9 +/- 8.4% and that of the sixth dose was 67.9 +/- 25.9% (p less than 0.05) in the other ten patients.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),%,67.9,210932,DB01223,Aminophylline
,6686557,steady-state plasma theophylline concentrations,"Morning and night steady-state plasma theophylline concentrations during a continuous intravenous infusion of aminophylline were not different (14.9 +/- 5.3 mg/l vs. 15.6 +/- 5.9 mg/l), demonstrating that there was no diurnal variation in the plasma clearance of theophylline.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),[mg] / [l],15.6,210933,DB01223,Aminophylline
,1650860,half-life,There was no significant difference in theophylline half-life before treatment (7.25 +/- 2.43 hr) and after treatment (7.82 +/- 3.35 hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),h,7.25,211413,DB01223,Aminophylline
,1650860,half-life,There was no significant difference in theophylline half-life before treatment (7.25 +/- 2.43 hr) and after treatment (7.82 +/- 3.35 hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),h,7.82,211414,DB01223,Aminophylline
,1650860,clearance,There was no significant difference in theophylline clearance before treatment (0.047 +/- 0.018 L/kg/hr) and after treatment (0.047 +/- 0.020 L/kg/hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),[l] / [h·kg],0.047,211415,DB01223,Aminophylline
,1650860,clearance,There was no significant difference in theophylline clearance before treatment (0.047 +/- 0.018 L/kg/hr) and after treatment (0.047 +/- 0.020 L/kg/hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),[l] / [h·kg],0.047,211416,DB01223,Aminophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB01223,Aminophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB01223,Aminophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB01223,Aminophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB01223,Aminophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB01223,Aminophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB01223,Aminophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB01223,Aminophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB01223,Aminophylline
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB01223,Aminophylline
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB01223,Aminophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],233,217325,DB01223,Aminophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],191,217326,DB01223,Aminophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],242,217327,DB01223,Aminophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],212,217328,DB01223,Aminophylline
,8888069,Clearance,"Clearance of theophylline was significantly higher after CSF administration (0.76 vs 0.99 ml/min/kg, p = 0.019).","The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888069/),[ml] / [kg·min],0.76,218776,DB01223,Aminophylline
,8888069,Clearance,"Clearance of theophylline was significantly higher after CSF administration (0.76 vs 0.99 ml/min/kg, p = 0.019).","The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888069/),[ml] / [kg·min],0.99,218777,DB01223,Aminophylline
,10939036,Cmax,"In Steps I and II, Cmax was 10.8 +/- 1.1 and 10.8 +/- 0.8 micrograms/ml, respectively.",Usefulness and safety of theophylline injection form (Theodrip) for the treatment of acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939036/),[μg] / [ml],10.8,221462,DB01223,Aminophylline
,10939036,Cmax,"In Steps I and II, Cmax was 10.8 +/- 1.1 and 10.8 +/- 0.8 micrograms/ml, respectively.",Usefulness and safety of theophylline injection form (Theodrip) for the treatment of acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939036/),[μg] / [ml],10.8,221463,DB01223,Aminophylline
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],39.5,221491,DB01223,Aminophylline
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],28.1,221492,DB01223,Aminophylline
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,7.3,221493,DB01223,Aminophylline
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,10.1,221494,DB01223,Aminophylline
,2791443,Clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],6.01 x 10(-2),222364,DB01223,Aminophylline
,2791443,clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],4.09 x 10(-2),222365,DB01223,Aminophylline
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,6.93,222366,DB01223,Aminophylline
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,8.69,222367,DB01223,Aminophylline
,2791443,mean residence time,The mean residence time for passive smokers was 9.89 hours.,Effects of passive smoking on theophylline clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,9.89,222368,DB01223,Aminophylline
,2791443,mean residence time,"For nonsmokers, the mean residence time was 13.11 hours (p less than 0.05).",Effects of passive smoking on theophylline clearance. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,13.11,222369,DB01223,Aminophylline
,11591894,Total body clearance,"Total body clearance of theophylline was significantly elevated in the children exposed to environmental tobacco smoke (1.36 +/- 0.09 vs. 0.90 +/- 0.04 mL/min per kg, p < 0.0001).",Effect of passive smoking on theophylline clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),[ml] / [kg·min],1.36,222801,DB01223,Aminophylline
,11591894,Total body clearance,"Total body clearance of theophylline was significantly elevated in the children exposed to environmental tobacco smoke (1.36 +/- 0.09 vs. 0.90 +/- 0.04 mL/min per kg, p < 0.0001).",Effect of passive smoking on theophylline clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),[ml] / [kg·min],0.90,222802,DB01223,Aminophylline
,11591894,Steady-state serum levels,Steady-state serum levels were significantly lower in the passive smoking group (55.3 +/- 2.8 vs. 73.2 +/- 3.3 p < 0.00001) for those receiving nearly identical intravenous doses.,Effect of passive smoking on theophylline clearance in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),,55.3,222803,DB01223,Aminophylline
,11591894,Steady-state serum levels,Steady-state serum levels were significantly lower in the passive smoking group (55.3 +/- 2.8 vs. 73.2 +/- 3.3 p < 0.00001) for those receiving nearly identical intravenous doses.,Effect of passive smoking on theophylline clearance in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),,73.2,222804,DB01223,Aminophylline
,11591894,length of hospital stay,"The length of hospital stay was longer in the group exposed to passive smoke (4.4 +/- 2.6 vs. 2.9 +/- 1.3 days, p < 0.05).",Effect of passive smoking on theophylline clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),d,4.4,222805,DB01223,Aminophylline
,11591894,length of hospital stay,"The length of hospital stay was longer in the group exposed to passive smoke (4.4 +/- 2.6 vs. 2.9 +/- 1.3 days, p < 0.05).",Effect of passive smoking on theophylline clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),d,2.9,222806,DB01223,Aminophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,93.6,222883,DB01223,Aminophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,105.6,222884,DB01223,Aminophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,110.8,222885,DB01223,Aminophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,120.1,222886,DB01223,Aminophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.89,222887,DB01223,Aminophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.59,222888,DB01223,Aminophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.35,222889,DB01223,Aminophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.20,222890,DB01223,Aminophylline
,1983143,renal clearance,Unchanged drug (11.6% +/- 1.75) was excreted in the urine corresponding to a renal clearance of 10.6 +/- 1.6 mL h-1kg-1.,Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [h],10.6,222900,DB01223,Aminophylline
,1983143,renal clearance,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[l] / [h·kg],0.58,222901,DB01223,Aminophylline
,1983143,renal clearance,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[l] / [h·kg],0.23,222902,DB01223,Aminophylline
,1983143,urine flow rate,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [min],1.1,222903,DB01223,Aminophylline
,1983143,urine flow rate,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [min],1.8,222904,DB01223,Aminophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.624,224892,DB01223,Aminophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.616,224893,DB01223,Aminophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.593,224894,DB01223,Aminophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,22.1,224895,DB01223,Aminophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,9.9,224896,DB01223,Aminophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,15.8,224897,DB01223,Aminophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],34.02,224898,DB01223,Aminophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],49.20,224899,DB01223,Aminophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],29.24,224900,DB01223,Aminophylline
,7031111,apparent volume of distribution,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[l] / [kg],0.45,225059,DB01223,Aminophylline
,7031111,apparent volume of distribution,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[l] / [kg],0.41,225060,DB01223,Aminophylline
,7031111,clearance,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[min·ml] / [kg],0.83,225061,DB01223,Aminophylline
,7031111,clearance,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[min·ml] / [kg],0.60,225062,DB01223,Aminophylline
,7031111,elimination half-life,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),h,6.65,225063,DB01223,Aminophylline
,7031111,elimination half-life,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),h,8.10,225064,DB01223,Aminophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],8.15,226329,DB01223,Aminophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],12.37,226330,DB01223,Aminophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],6.26,226331,DB01223,Aminophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],9.96,226332,DB01223,Aminophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],11.91,226333,DB01223,Aminophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],17.13,226334,DB01223,Aminophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],8.17,226335,DB01223,Aminophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],13.02,226336,DB01223,Aminophylline
,7400475,peak concentration,"In the fasting subjects solutions given orally were absorbed faster (0.95 versus 1.95 hr to peak), reaching a higher peak concentration (7.26 versus 4.87 microgram/ml) than the solutions given rectally.",Bioavailability of theophylline following a rectally administered concentrated aminophylline solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400475/),[μg] / [ml],7.26,229214,DB01223,Aminophylline
,7400475,peak concentration,"In the fasting subjects solutions given orally were absorbed faster (0.95 versus 1.95 hr to peak), reaching a higher peak concentration (7.26 versus 4.87 microgram/ml) than the solutions given rectally.",Bioavailability of theophylline following a rectally administered concentrated aminophylline solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400475/),[μg] / [ml],4.87,229215,DB01223,Aminophylline
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],43,229967,DB01223,Aminophylline
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],42,229968,DB01223,Aminophylline
,8193433,total body clearance,A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 +/- 2.8 to 43.4 +/- 4.7 mL/kg/h [mean +/- SEM]; p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),[ml] / [h·kg],21.7,230969,DB01223,Aminophylline
,8193433,total body clearance,A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 +/- 2.8 to 43.4 +/- 4.7 mL/kg/h [mean +/- SEM]; p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),[ml] / [h·kg],43.4,230970,DB01223,Aminophylline
,8193433,elimination half-life,The theophylline elimination half-life prior to treatment was 18.2 +/- 2.2 hours and decreased to 9.1 +/- 0.8 hours following treatment (p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),h,18.2,230971,DB01223,Aminophylline
,8193433,elimination half-life,The theophylline elimination half-life prior to treatment was 18.2 +/- 2.2 hours and decreased to 9.1 +/- 0.8 hours following treatment (p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),h,9.1,230972,DB01223,Aminophylline
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,6.72,231707,DB01223,Aminophylline
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,7.02,231708,DB01223,Aminophylline
,6885207,total body clearance,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),[l] / [h·kg],0.054,232144,DB01223,Aminophylline
,6885207,elimination half-life,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),h,6.0,232145,DB01223,Aminophylline
,6885207,volume of distribution,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),[l] / [kg],0.455,232146,DB01223,Aminophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,94,232147,DB01223,Aminophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,88,232148,DB01223,Aminophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,84,232149,DB01223,Aminophylline
,25323694,peak concentrations (C max),"Following intravenous and oral administration, the peak concentrations (C max) were found to be (16.5 ± 3.0) µg/mL at (0.08 ± 0) h and (7.4 ± 1.5) µg/mL at (1.83 ± 1.11) h, respectively.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[μg] / [ml],16.5,233299,DB01223,Aminophylline
,25323694,peak concentrations (C max),"Following intravenous and oral administration, the peak concentrations (C max) were found to be (16.5 ± 3.0) µg/mL at (0.08 ± 0) h and (7.4 ± 1.5) µg/mL at (1.83 ± 1.11) h, respectively.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[μg] / [ml],7.4,233300,DB01223,Aminophylline
,25323694,elimination half-time (t 1/2),"The elimination half-time (t 1/2) after intravenous and oral administration were, respectively, (13.1 ± 4.17) h and (11.65 ± 1.14) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,13.1,233301,DB01223,Aminophylline
,25323694,elimination half-time (t 1/2),"The elimination half-time (t 1/2) after intravenous and oral administration were, respectively, (13.1 ± 4.17) h and (11.65 ± 1.14) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,11.65,233302,DB01223,Aminophylline
,25323694,Areas under the plasma concentration-time curve (AUC),"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],209.6,233303,DB01223,Aminophylline
,25323694,AUC0-t,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],209.6,233304,DB01223,Aminophylline
,25323694,AUC0→∞,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],219.5,233305,DB01223,Aminophylline
,25323694,AUC0-t,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],165.1,233306,DB01223,Aminophylline
,25323694,AUC0→∞,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],179.3,233307,DB01223,Aminophylline
,25323694,retention time (MRT),"Mean retention time (MRT) after intravenous and oral administration were, respectively, (14.06 ± 0.86) and (15.27 ± 0.62) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,14.06,233308,DB01223,Aminophylline
,25323694,retention time (MRT),"Mean retention time (MRT) after intravenous and oral administration were, respectively, (14.06 ± 0.86) and (15.27 ± 0.62) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,15.27,233309,DB01223,Aminophylline
,25323694,total clearance rates (CLtol),The total clearance rates (CLtol) were (0.77 ± 0.10) mL min(-1) kg(-1) of intravenous and (0.97 ± 0.20) mL min(-1) kg(-1) of oral administration.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[ml] / [kg·min],0.77,233310,DB01223,Aminophylline
,25323694,total clearance rates (CLtol),The total clearance rates (CLtol) were (0.77 ± 0.10) mL min(-1) kg(-1) of intravenous and (0.97 ± 0.20) mL min(-1) kg(-1) of oral administration.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[ml] / [kg·min],0.97,233311,DB01223,Aminophylline
,25323694,apparent distribution volume (V d),"The apparent distribution volume (V d) was (0.87 ± 0.27) and (0.97 ± 0.20) L kg(-1), respectively, for intravenous and oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[l] / [kg],0.87,233312,DB01223,Aminophylline
,25323694,apparent distribution volume (V d),"The apparent distribution volume (V d) was (0.87 ± 0.27) and (0.97 ± 0.20) L kg(-1), respectively, for intravenous and oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[l] / [kg],0.97,233313,DB01223,Aminophylline
,25323694,absolute bioavailability (F),The absolute bioavailability (F) after oral administration was (83.1 ± 11.7) %.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),%,83.1,233314,DB01223,Aminophylline
,2121750,clearance,Group I patients had a lower mean theophylline clearance of 0.42 +/- 0.23 ml/kg/min compared to Group II 0.64 +/- 0.24 ml/kg/min (P = 0.003).,Theophylline plasma clearance in critically ill geriatric patients receiving total parenteral nutrition and in control patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121750/),[ml] / [kg·min],0.42,237212,DB01223,Aminophylline
,2121750,clearance,Group I patients had a lower mean theophylline clearance of 0.42 +/- 0.23 ml/kg/min compared to Group II 0.64 +/- 0.24 ml/kg/min (P = 0.003).,Theophylline plasma clearance in critically ill geriatric patients receiving total parenteral nutrition and in control patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121750/),[ml] / [kg·min],0.64,237213,DB01223,Aminophylline
,10893702,plasma concentrations,"2) After the intravenous bolus injection (30 sec) and the 15-min constant rate infusion of theophylline to dogs, the plasma concentrations of theophylline were 27.37 +/- 3.67 micrograms/ml and 18.34 +/- 2.32 micrograms/ml immediately after the completion of administration, respectively.",Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893702/),[μg] / [ml],27.37,241263,DB01223,Aminophylline
,10893702,plasma concentrations,"2) After the intravenous bolus injection (30 sec) and the 15-min constant rate infusion of theophylline to dogs, the plasma concentrations of theophylline were 27.37 +/- 3.67 micrograms/ml and 18.34 +/- 2.32 micrograms/ml immediately after the completion of administration, respectively.",Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893702/),[μg] / [ml],18.34,241264,DB01223,Aminophylline
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],189.9,244120,DB01223,Aminophylline
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],274.9,244121,DB01223,Aminophylline
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],28.4,244122,DB01223,Aminophylline
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],19.8,244123,DB01223,Aminophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],0.69,244982,DB01223,Aminophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],1.37,244983,DB01223,Aminophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],2.62,244984,DB01223,Aminophylline
,25150710,k(e0),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),1/[min],0.805,244985,DB01223,Aminophylline
,25150710,E0,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.76,244986,DB01223,Aminophylline
,25150710,Emax,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.398,244987,DB01223,Aminophylline
,25150710,Ce(50 na),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],2.38,244988,DB01223,Aminophylline
,25150710,C(e50 wa),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],4.49,244989,DB01223,Aminophylline
,25150710,γ,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,2.21,244990,DB01223,Aminophylline
,10850374,volume of distribution,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[l] / [kg],0.937,245772,DB01223,Aminophylline
,10850374,elimination rate constant,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0249,245773,DB01223,Aminophylline
,10850374,elimination half-life,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,32.1,245774,DB01223,Aminophylline
,10850374,total body clearance,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[ml] / [h·kg],21.7,245775,DB01223,Aminophylline
,10850374,elimination half-life,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,95.1,245776,DB01223,Aminophylline
,10850374,elimination rate constant,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0079,245777,DB01223,Aminophylline
,10850374,serum concentrations,"The mean (+/- S.E.M.) serum concentrations of theophylline and caffeine on the sixth day after aminophylline infusion were 10.4 +/- 2.28 microg/ml (range, 6.38-13.4 microg/ml) and 2.94 +/- 0.98 microg/ml (range, 1.80-4.44 microg/ml), respectively.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[μg] / [ml],2.94,245778,DB01223,Aminophylline
,10850374,concentration ratio,"The mean (+/- S.E.M.) caffeine to theophylline concentration ratio on the day after discontinuation of aminophylline infusion was 0.71 +/- 0.23 (range, 0.39-1.03).",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),,0.71,245779,DB01223,Aminophylline
,6638669,half-life,"The theophylline half-life was reduced with charcoal from 10.2 to 4.6 h (p less than 0.001), and clearance increased from 35.6 to 72.6 ml/kg/h (p less than 0.001).",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,10.2 to 4.6,248440,DB01223,Aminophylline
,6638669,clearance,"The theophylline half-life was reduced with charcoal from 10.2 to 4.6 h (p less than 0.001), and clearance increased from 35.6 to 72.6 ml/kg/h (p less than 0.001).",Increased serum theophylline clearance with orally administered activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),[ml] / [h·kg],35.6 to 72.6,248441,DB01223,Aminophylline
,6638669,half-life,"In a patient with an initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity (arrhythmias and seizures), the administration of charcoal (4 doses of 30 g every 2 h) reduced the half-life from 34.4 to 5.7 h concomitant with rapid resolution of signs of toxicity.",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,34.4,248442,DB01223,Aminophylline
,6638669,half-life,"In a patient with an initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity (arrhythmias and seizures), the administration of charcoal (4 doses of 30 g every 2 h) reduced the half-life from 34.4 to 5.7 h concomitant with rapid resolution of signs of toxicity.",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,5,248443,DB01223,Aminophylline
,3429057,time required to reach maximum plasma concentration,The in vivo studies demonstrated that the time required to reach maximum plasma concentration of theophylline was about 8 h.,"Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,8,251881,DB01223,Aminophylline
,3429057,mean residence time,"The mean residence time in vivo, MRT, was 18.6 h.","Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,18.6,251882,DB01223,Aminophylline
,3429057,MRT,"The mean residence time in vivo, MRT, was 18.6 h.","Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,18.6,251883,DB01223,Aminophylline
,3678595,maximum plasma concentration,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),[μg] / [ml],3.19,254053,DB01223,Aminophylline
,3678595,maximum plasma concentration,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),[μg] / [ml],4.51,254054,DB01223,Aminophylline
,3678595,time needed to reach this,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),h,8.71,254055,DB01223,Aminophylline
,3678595,time needed to reach this,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),h,1.96,254056,DB01223,Aminophylline
,3678595,absolute,"Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (+/- SD) 92.7 +/- 23.2% and 83.14 +/- 14.69%, respectively.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),%,92.7,254057,DB01223,Aminophylline
,3678595,relative percentage bioavailabilities,"Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (+/- SD) 92.7 +/- 23.2% and 83.14 +/- 14.69%, respectively.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),%,83.14,254058,DB01223,Aminophylline
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],4.22,254110,DB01223,Aminophylline
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],8.02,254111,DB01223,Aminophylline
,7223441,kel,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00457,254447,DB01223,Aminophylline
,7223441,beta,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00296,254448,DB01223,Aminophylline
,7223441,clearance,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[-1·min·ml] / [kg],2.04,254449,DB01223,Aminophylline
,7223441,Vd beta,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[ml] / [kg],693,254450,DB01223,Aminophylline
,7223441,kel,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00293,254451,DB01223,Aminophylline
,7223441,kel,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00198,254452,DB01223,Aminophylline
,7223441,clearance,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[-1·min·ml] / [kg],1.50,254453,DB01223,Aminophylline
,7223441,Vd beta,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[ml] / [kg],757,254454,DB01223,Aminophylline
,7223441,general plasma concentration level,The general plasma concentration level was 0-1.8 . 10(-8) mol ml-1 (0-3 microgram ml-1).,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[mol] / [ml],0-1.8 .,254455,DB01223,Aminophylline
,28761582,trough amikacin concentration,"Mean (SD) trough amikacin concentration (from samples collected 30 minutes before the fourth dose) among term (n = 25), and preterm (<37 weeks' gestation n = 36) neonates were 6.2 (3.4) and 9.2 (5.7) µg/mL, respectively (P = 0.02).",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),[μg] / [ml],6.2,255576,DB01223,Aminophylline
,28761582,trough amikacin concentration,"Mean (SD) trough amikacin concentration (from samples collected 30 minutes before the fourth dose) among term (n = 25), and preterm (<37 weeks' gestation n = 36) neonates were 6.2 (3.4) and 9.2 (5.7) µg/mL, respectively (P = 0.02).",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),[μg] / [ml],9.2,255577,DB01223,Aminophylline
,28761582,V (L),"The population CL and V of amikacin were related as CL (L/h) = 0.153 (birth weight/2.5)1.31, V (L) = 2.94 (birth weight/2.5)1.18.",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),,2,255578,DB01223,Aminophylline
,28761582,CL,"CL and V were 0.058 L/h/kg and 1.15 L/kg, respectively, for a mean birth weight of 2.1 kg, and the mean half-life (based on 1-compartment model), was 13.7 hours.",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),[l] / [h·kg],0.058,255579,DB01223,Aminophylline
,28761582,V,"CL and V were 0.058 L/h/kg and 1.15 L/kg, respectively, for a mean birth weight of 2.1 kg, and the mean half-life (based on 1-compartment model), was 13.7 hours.",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),[l] / [kg],1.15,255580,DB01223,Aminophylline
,28761582,half-life,"CL and V were 0.058 L/h/kg and 1.15 L/kg, respectively, for a mean birth weight of 2.1 kg, and the mean half-life (based on 1-compartment model), was 13.7 hours.",Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761582/),h,13.7,255581,DB01223,Aminophylline
,2614856,elimination rate constant (lambda z),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),1/[h],0.07,261352,DB01223,Aminophylline
,2614856,apparent volume of distribution (Vz),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[l] / [kg],0.80,261353,DB01223,Aminophylline
,2614856,clearance (Cl),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[l] / [h·kg],0.06,261354,DB01223,Aminophylline
,2614856,Mean residence time,Mean residence time determined by statistical moment theory of the oral data was different (P less than 0.05) for the immediate-release aminophylline (13.8 +/- 2.8 h) and sustained-release theophylline (18.2 +/- 2.3 h) formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),h,13.8,261355,DB01223,Aminophylline
,2614856,Mean residence time,Mean residence time determined by statistical moment theory of the oral data was different (P less than 0.05) for the immediate-release aminophylline (13.8 +/- 2.8 h) and sustained-release theophylline (18.2 +/- 2.3 h) formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),h,18.2,261356,DB01223,Aminophylline
,2614856,peak theophylline plasma concentration,Immediate-release aminophylline tablets quickly achieved peak theophylline plasma concentration of 11.51 +/- 1.4 micrograms/ml at 1.6 +/- 0.6 h while the sustained-release theophylline tablets were more slowly absorbed and achieved peak theophylline concentrations of 17.20 +/- 1.3 micrograms/ml at 7.3 +/- 1.0 h.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],11.51,261357,DB01223,Aminophylline
,2614856,peak theophylline concentrations,Immediate-release aminophylline tablets quickly achieved peak theophylline plasma concentration of 11.51 +/- 1.4 micrograms/ml at 1.6 +/- 0.6 h while the sustained-release theophylline tablets were more slowly absorbed and achieved peak theophylline concentrations of 17.20 +/- 1.3 micrograms/ml at 7.3 +/- 1.0 h.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],17.20,261358,DB01223,Aminophylline
,2614856,Absolute bioavailability,Absolute bioavailability was 87% for the immediate-release and 97% for the sustained-release formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),%,87,261359,DB01223,Aminophylline
,2614856,Absolute bioavailability,Absolute bioavailability was 87% for the immediate-release and 97% for the sustained-release formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),%,97,261360,DB01223,Aminophylline
,2614856,trough-peak,"Using the principle of superposition, a loading dose of 20 mg/kg of the sustained-release formulation followed by maintenance doses of 15 mg/kg every 24 h was predicted to achieve trough-peak theophylline plasma concentrations between 6 and 17 micrograms/ml.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],6 and 17,261361,DB01223,Aminophylline
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,7.59,262576,DB01223,Aminophylline
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,9.05,262577,DB01223,Aminophylline
,7229966,half-life,"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),h,2.8,263321,DB01223,Aminophylline
,7229966,volume of distribution,"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),h,4.4,263322,DB01223,Aminophylline
,7229966,Vd(beta),"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),[l] / [kg],0.708,263323,DB01223,Aminophylline
>,7612107,peak STCs,Five patients had peak STCs in the toxic range (> 20 micrograms/ml).,Theophylline pharmacokinetics in Thai children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[μg] / [ml],20,269778,DB01223,Aminophylline
,7612107,plasma half life (t1/2),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),h,3.08,269779,DB01223,Aminophylline
,7612107,elimination rate constant (Kel),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),1/[h],0.26,269780,DB01223,Aminophylline
,7612107,absorption rate constant (Ka),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),1/[h],2.21,269781,DB01223,Aminophylline
,7612107,volume of distribution (Vd),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[l] / [kg],0.23,269782,DB01223,Aminophylline
,7612107,plasma clearance (CI),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[ml] / [h·kg],56,269783,DB01223,Aminophylline
,2737801,terminal elimination rate constant,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),1/[h],0.119 to 0.101,271508,DB01223,Aminophylline
,2737801,total body clearance,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],31.2 to 26.5,271509,DB01223,Aminophylline
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,16.3,271510,DB01223,Aminophylline
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,15.5,271511,DB01223,Aminophylline
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],4.5,271512,DB01223,Aminophylline
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],3.9,271513,DB01223,Aminophylline
,7438680,Total body clearances,Total body clearances of theophylline were 29.5 +/- 7.8 ml/hr/kg TBW and 58.8 +/- 15.9 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],29.5,272726,DB01223,Aminophylline
,7438680,Total body clearances,Total body clearances of theophylline were 29.5 +/- 7.8 ml/hr/kg TBW and 58.8 +/- 15.9 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],58.8,272727,DB01223,Aminophylline
,7438680,ClT,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],19.7,272728,DB01223,Aminophylline
,7438680,ClT,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],47.7,272729,DB01223,Aminophylline
,7438680,clearance,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],34.5,272730,DB01223,Aminophylline
,7438680,clearance,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],64.3,272731,DB01223,Aminophylline
,7438680,ClT,Our data suggest that maintenance doses of theophylline in markedly obese patients with CHF should be based on a theophylline ClT of 19.7 ml/hr/kg TBW and of 34.5 ml/hr/kg TBW in those with no CHF.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],19.7,272732,DB01223,Aminophylline
,7438680,ClT,Our data suggest that maintenance doses of theophylline in markedly obese patients with CHF should be based on a theophylline ClT of 19.7 ml/hr/kg TBW and of 34.5 ml/hr/kg TBW in those with no CHF.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],34.5,272733,DB01223,Aminophylline
